Dihydrocodeine

Sources

12 strong · 23 moderate · 5 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked

76verified11partial10inconclusive1not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated

May 9, 2026 · pipeline-v5

Values approved

101/101 (100%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	20 mg	20 mg	medium
Low	50–100 mg	50–100 mg	medium
Common	100–150 mg	100–150 mg	medium
Strong	150–200 mg	150–200 mg	medium
Heavy	200+ mg	200+ mg	medium
Editorial	Dose ranges from existing DB, consistent with clinical therapeutic ranges (30–120 mg BID in Freye 2001, Ammon 1999, Pedersen 2014). Bioavailability 21% (range 12–34%) from Rowell 1983. No controlled recreational dose-ranging study exists; ranges likely reflect non-tolerant recreational use rather than clinical prescribing. Safety-critical: these ranges should be understood as community consensus backed by clinical plausibility, not direct experimental evidence for recreational dosing.
	ReasoningReasoning Dose ranges from existing DB, consistent with clinical therapeutic ranges (30–120 mg BID in Freye 2001, Ammon 1999, Pedersen 2014). Bioavailability 21% (range 12–34%) from Rowell 1983. No controlled recreational dose-ranging study exists; ranges likely reflect non-tolerant recreational use rather than clinical prescribing. Safety-critical: these ranges should be understood as community consensus backed by clinical plausibility, not direct experimental evidence for recreational dosing. Evidence basis: community_consensus_large

Duration

oral

Field	Published	AI Proposed	Confidence
Onsettrace	30–60 minutes	30–60 minutes	medium
Editorial	Work-notes specify onset 30–60 min. Consistent with Rowell 1983 Tmax of 1.6–1.8h — first perceptible effects expected well before peak plasma concentration.
	ReasoningReasoning Work-notes specify onset 30–60 min. Consistent with Rowell 1983 Tmax of 1.6–1.8h — first perceptible effects expected well before peak plasma concentration. Evidence basis: controlled_human_study
Come uptrace	30–60 minutes	30–60 minutes	medium
Editorial	Work-notes specify come_up 30–60 min. Effects build as plasma concentrations approach Tmax (1.6–1.8h, Rowell 1983).
	ReasoningReasoning Work-notes specify come_up 30–60 min. Effects build as plasma concentrations approach Tmax (1.6–1.8h, Rowell 1983). Evidence basis: controlled_human_study
Peaktrace	1–2 hours	1–2 hours	medium
Editorial	Work-notes specify peak 1–2 hours. Corresponds to plateau around Tmax (1.6–1.8h) through early elimination phase. Consistent with 3.3–4.5h half-life from Rowell 1983.
	ReasoningReasoning Work-notes specify peak 1–2 hours. Corresponds to plateau around Tmax (1.6–1.8h) through early elimination phase. Consistent with 3.3–4.5h half-life from Rowell 1983. Evidence basis: controlled_human_study
Offsettrace	1–2 hours	1–2 hours	medium
Editorial	Work-notes specify offset 1–2 hours. Effects diminish as plasma levels decline through elimination half-life (3.3–4.5h, Rowell 1983).
	ReasoningReasoning Work-notes specify offset 1–2 hours. Effects diminish as plasma levels decline through elimination half-life (3.3–4.5h, Rowell 1983). Evidence basis: controlled_human_study
Totaltrace	4–6 hours	4–6 hours	medium
Editorial	Work-notes recommend 4–6 hours over existing DB value of 3–4 hours, as the latter is inconsistent with the 3.3–4.5h elimination half-life (Rowell 1983). 4–6h more accurately reflects subjective duration for immediate-release formulations.
	ReasoningReasoning Work-notes recommend 4–6 hours over existing DB value of 3–4 hours, as the latter is inconsistent with the 3.3–4.5h elimination half-life (Rowell 1983). 4–6h more accurately reflects subjective duration for immediate-release formulations. Evidence basis: controlled_human_study
After effectstrace	2–6 hours	2–6 hours	medium
Editorial	Work-notes specify aftereffects 2–6 hours. Residual sedation and constipation may persist after subjective opioid effects end. Consistent with elimination kinetics.
	ReasoningReasoning Work-notes specify aftereffects 2–6 hours. Residual sedation and constipation may persist after subjective opioid effects end. Consistent with elimination kinetics. Evidence basis: controlled_human_study

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	high	high	high
Chronic	moderate	moderate	high
Organs Affected	pulmonary, renal, gastrointestinal	pulmonary, renal, gastrointestinal	high
Editorial	Work-notes specify acute=high (supported by Rock 2022 fatality trends, Klinder 1999 and Aderjan 1998 post-mortem data) and chronic=moderate (constipation via Freye 2001, renal glucuronide accumulation via Barnes 1985 case reports, but no hepatotoxicity). Confidence is high for acute (multiple independent fatal case series), medium for chronic (no DHC-specific endocrine data; class-extrapolated). Using high overall as work-notes specify.
	ReasoningReasoning Work-notes specify acute=high (supported by Rock 2022 fatality trends, Klinder 1999 and Aderjan 1998 post-mortem data) and chronic=moderate (constipation via Freye 2001, renal glucuronide accumulation via Barnes 1985 case reports, but no hepatotoxicity). Confidence is high for acute (multiple independent fatal case series), medium for chronic (no DHC-specific endocrine data; class-extrapolated). Using high overall as work-notes specify. Evidence basis: published_case_series

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	moderate	moderate	medium
Psychological	moderate	moderate	medium
Compulsive Redosing	moderate	moderate	medium
Dose Escalation	moderate	moderate	medium
Editorial	Work-notes specify moderate physical and psychological dependence. Dependence documented through clinical substitution use (Oldham 2004 LEEDS study) and pharmacovigilance signals (Chiappini 2022). All withdrawal parameters are class-extrapolated from short-acting opioids (codeine, morphine) — no DHC-specific withdrawal characterization study exists.
	ReasoningReasoning Work-notes specify moderate physical and psychological dependence. Dependence documented through clinical substitution use (Oldham 2004 LEEDS study) and pharmacovigilance signals (Chiappini 2022). All withdrawal parameters are class-extrapolated from short-acting opioids (codeine, morphine) — no DHC-specific withdrawal characterization study exists. Evidence basis: community_consensus_large

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	moderate	moderate	low
Symptoms	anxiety, restlessness, irritability, dysphoria, myalgia, lacrimation, rhinorrhea, yawning, insomnia, diarrhea, nausea, vomiting, cravings	anxiety, restlessness, irritability, dysphoria, myalgia, lacrimation, rhinorrhea, yawning, insomnia, diarrhea, nausea, vomiting, cravings	low
Fatal	No	No	low
Medical Supervision	Not required	Not required	low
Editorial	Withdrawal profile extrapolated from short-acting opioid class (codeine, morphine). Work-notes estimate onset 8–24 hours (midpoint 12h used), duration 5–10 days (midpoint 8 days). No DHC-specific withdrawal characterization study exists. Severity rated moderate per class analogy — opioid withdrawal is intensely uncomfortable but not life-threatening.
	ReasoningReasoning Withdrawal profile extrapolated from short-acting opioid class (codeine, morphine). Work-notes estimate onset 8–24 hours (midpoint 12h used), duration 5–10 days (midpoint 8 days). No DHC-specific withdrawal characterization study exists. Severity rated moderate per class analogy — opioid withdrawal is intensely uncomfortable but not life-threatening. Evidence basis: community_consensus_large

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	moderate	moderate	low
Half-life	5 days	5 days	low
Full Reset	10.5 days	10.5 days	low
Cross-tolerances	opioids	opioids	low
Editorial	Work-notes flag tolerance half-life and reset values as unconfirmed by published sources — inferred from short-acting opioid class (codeine, morphine). Mechanism is well-established for mu-opioid agonists. Cross-tolerance with all opioids is high-confidence. Specific kinetic values are low-confidence editorial estimates.
	ReasoningReasoning Work-notes flag tolerance half-life and reset values as unconfirmed by published sources — inferred from short-acting opioid class (codeine, morphine). Mechanism is well-established for mu-opioid agonists. Cross-tolerance with all opioids is high-confidence. Specific kinetic values are low-confidence editorial estimates. Evidence basis: structural_analogy

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
respiratory Respiratory insufficiencytrace	absolute	absolute	high
Editorial	Work-notes list respiratory_insufficiency as absolute contraindication with high confidence. Article prose and research output confirm respiratory depression as dose-limiting toxicity and primary mechanism of DHC-related death (Rock 2022, Klinder 1999).
	ReasoningReasoning Work-notes list respiratory_insufficiency as absolute contraindication with high confidence. Article prose and research output confirm respiratory depression as dose-limiting toxicity and primary mechanism of DHC-related death (Rock 2022, Klinder 1999).
hepatic Severe hepatic impairmenttrace	absolute	absolute	high
Editorial	Work-notes list severe_hepatic_impairment as absolute contraindication with high confidence. Article prose cites Tegeder 1999 and Barnes 2006 confirming increased bioavailability and decreased clearance in hepatic disease.
	ReasoningReasoning Work-notes list severe_hepatic_impairment as absolute contraindication with high confidence. Article prose cites Tegeder 1999 and Barnes 2006 confirming increased bioavailability and decreased clearance in hepatic disease.
renal Severe renal impairmenttrace	absolute	absolute	high
Editorial	Work-notes list severe_renal_impairment as absolute contraindication with high confidence. Article prose cites case reports (Barnes 1985, Palliative Medicine 2011) documenting prolonged narcosis from glucuronide accumulation in renal failure.
	ReasoningReasoning Work-notes list severe_renal_impairment as absolute contraindication with high confidence. Article prose cites case reports (Barnes 1985, Palliative Medicine 2011) documenting prolonged narcosis from glucuronide accumulation in renal failure.
other Concurrent MAO inhibitor usetrace	absolute	absolute	medium
Editorial	Work-notes list maoi_concurrent_use as absolute contraindication with medium confidence. Class-level opioid contraindication; no DHC-specific reports but mechanism is well-established.
	ReasoningReasoning Work-notes list maoi_concurrent_use as absolute contraindication with medium confidence. Class-level opioid contraindication; no DHC-specific reports but mechanism is well-established.
age Neonates and infantstrace	absolute	absolute	high
Editorial	Work-notes list neonates_infants as absolute contraindication with high confidence. Shimizu 2018 case report provides direct evidence of neonatal toxicity from impaired glucuronidation.
	ReasoningReasoning Work-notes list neonates_infants as absolute contraindication with high confidence. Shimizu 2018 case report provides direct evidence of neonatal toxicity from impaired glucuronidation.
metabolic CYP2D6 ultrarapid metabolizer statustrace	relative	relative	medium
Editorial	Work-notes list cyp2d6_ultrarapid as relative contraindication with medium confidence. Research output confirms 70-fold mu-affinity differential between DHC and DHM (Schmidt 2002). No DHC-specific UM adverse event case reports, but mechanism is well-supported.
	ReasoningReasoning Work-notes list cyp2d6_ultrarapid as relative contraindication with medium confidence. Research output confirms 70-fold mu-affinity differential between DHC and DHM (Schmidt 2002). No DHC-specific UM adverse event case reports, but mechanism is well-supported.
other Concurrent CNS depressant usetrace	relative	relative	high
Editorial	Work-notes list concurrent_cns_depressants as relative contraindication with high confidence. Research output confirms lethal interaction severity for alcohol, GHB, GBL, and ketamine. Prescrire 2016 confirms comparable risk to low-dose morphine combinations.
	ReasoningReasoning Work-notes list concurrent_cns_depressants as relative contraindication with high confidence. Research output confirms lethal interaction severity for alcohol, GHB, GBL, and ketamine. Prescrire 2016 confirms comparable risk to low-dose morphine combinations.
psychiatric History of opioid use disordertrace	relative	relative	high
Editorial	Work-notes list opioid_use_disorder_history as relative contraindication with high confidence. Chiappini 2022 pharmacovigilance data and Täschner 1991 historical abuse patterns provide direct evidence.
	ReasoningReasoning Work-notes list opioid_use_disorder_history as relative contraindication with high confidence. Chiappini 2022 pharmacovigilance data and Täschner 1991 historical abuse patterns provide direct evidence.
neurological Raised intracranial pressuretrace	relative	relative	medium
Editorial	Work-notes list raised_icp as relative contraindication with medium confidence. Class-level opioid contraindication; no DHC-specific data but mechanism is well-established for all mu-opioid agonists.
	ReasoningReasoning Work-notes list raised_icp as relative contraindication with medium confidence. Class-level opioid contraindication; no DHC-specific data but mechanism is well-established for all mu-opioid agonists.
other Paralytic ileus or obstructive bowel diseasetrace	relative	relative	high
Editorial	Work-notes list ileus_obstruction as relative contraindication with high confidence. Freye 2001 provides direct controlled study evidence of DHC-induced GI motility reduction.
	ReasoningReasoning Work-notes list ileus_obstruction as relative contraindication with high confidence. Freye 2001 provides direct controlled study evidence of DHC-induced GI motility reduction.

Timeline Phases

oral

Field	Published	AI Proposed	Confidence
Onsettrace	1800–1800 sec(i=0.10)	1800–1800 sec(i=0.10)	medium
Editorial	Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section.
	ReasoningReasoning Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section. Evidence basis: controlled_human_study
Come uptrace	1800–3600 sec(i=0.40)	1800–3600 sec(i=0.40)	medium
Editorial	Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section.
	ReasoningReasoning Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section. Evidence basis: controlled_human_study
Peaktrace	5400–5400 sec(i=1.00)	5400–5400 sec(i=1.00)	medium
Editorial	Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section.
	ReasoningReasoning Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section. Evidence basis: controlled_human_study
Plateautrace	3600–7200 sec(i=0.50)	3600–7200 sec(i=0.50)	medium
Editorial	Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section.
	ReasoningReasoning Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section. Evidence basis: controlled_human_study
Resolutiontrace	3600–5400 sec(i=0.20)	3600–5400 sec(i=0.20)	medium
Editorial	Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section.
	ReasoningReasoning Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section. Evidence basis: controlled_human_study
Afterglowtrace	7200–10800 sec(i=0.15)	7200–10800 sec(i=0.15)	medium
Editorial	Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section.
	ReasoningReasoning Phase breakdown derived from Rowell 1983 PK parameters (Tmax 1.6–1.8h, half-life 3.3–4.5h) and work-notes timeline. Onset 0–30 min, come_up 30–90 min, peak 1.5–3h, offset/plateau 3–5h, afterglow 5–8h. Immediate-release formulation; controlled-release would extend substantially. Intensity weights from work-notes. Driving advisory from work-notes afterglow section. Evidence basis: controlled_human_study

Dose Tier Summaries

thresholdtrace

medium

At 20 mg oral, dihydrocodeine produces the faintest perceptible opioid effect. A subtle warmth may be noticed, along with very mild anxiety suppression and a slight lift in mood. There is no significant sedation or euphoria at this level. Physically, threshold doses fall below standard clinical therapeutic ranges and produce minimal somatic effects. Slight pupil constriction may occur but is unlikely to be noticed without measurement. Constipation and nausea are not expected. This dose may be sub-threshold for some opioid-naïve individuals. CYP2D6 ultrarapid metabolizers may perceive effects more readily due to greater dihydromorphine formation. Duration of perceptible effects is brief — approximately 2–3 hours.

Editorial

Work-notes specify threshold at 20 mg oral with minimal perceptible effects. Below clinical therapeutic doses (30–120 mg BID in studies). No controlled recreational dose-ranging study exists; values reflect existing DB data consistent with clinical ranges.

Reasoning

Evidence basis: community_consensus_large

lighttrace

medium

At 50–100 mg oral, mild analgesia and anxiety suppression become clearly apparent. A gentle body warmth spreads from the core, accompanied by mild sedation and subtle mood elevation. Cognitive effects are limited to slight thought deceleration and a quiet contentment. Physically, mild constipation and slight pupil constriction begin at this range. Some users report dry mouth. Nausea is possible but uncommon at these doses. Pain suppression is noticeable and comparable to low clinical therapeutic doses. Functional impairment is minimal but present — mild drowsiness may affect concentration. Duration spans approximately 4–5 hours for immediate-release formulations. Controlled-release preparations produce a flatter, more extended effect curve.

Editorial

Work-notes specify light at 50–100 mg oral with mild analgesia and anxiolysis. Consistent with low end of clinical dosing (30–120 mg BID). Freye 2001 documents 80% sedation/dry mouth at 60 mg CR, supporting onset of these effects at the light tier.

Reasoning

Evidence basis: community_consensus_large

commontrace

medium

At 100–150 mg oral, clear opioid effects emerge — a noticeable warmth envelops the body, moderate sedation sets in, and mild euphoria becomes apparent. Anxiety suppression is reliable, and cognitive euphoria manifests as quiet contentment. Thought deceleration is more pronounced, and emotional suppression may blunt affect. Physically, constipation is likely, pupil constriction is marked, and dry mouth is reported in approximately 80% of individuals at similar clinical doses (Freye 2001). Nausea becomes more common. Pain suppression is significant. Spontaneous body sensations — warmth and tingling — are characteristic. Driving and operating machinery are inadvisable. Duration is approximately 4–6 hours for immediate-release formulations. CYP2D6 genotype modulates intensity — ultrarapid metabolizers experience disproportionately greater effects.

Editorial

Work-notes specify common at 100–150 mg oral with clear opioid effects. Freye 2001 documents 80% dry mouth/sedation rates at 60–120 mg CR. Dose ranges are plausible and consistent with clinical data but no controlled recreational dose-ranging study exists.

Reasoning

Evidence basis: community_consensus_large

strongtrace

medium

At 150–200 mg oral, pronounced sedation dominates the experience. Marked euphoria and a deep body high are present, with significant cognitive impairment — thought deceleration, focus suppression, and motor control impairment become obvious. Emotional suppression is substantial. The urge for compulsive redosing may emerge. Physically, respiratory slowing becomes clinically relevant. Nausea and vomiting are common. Pupil constriction is pronounced, constipation is reliable, and physical fatigue is marked. Muscle relaxation is significant. Double vision may occur. This range exceeds standard clinical dosing. Risk of respiratory depression increases substantially, especially in opioid-naïve individuals, CYP2D6 ultrarapid metabolizers, or those with hepatic/renal impairment. Duration extends to 5–6 hours with lingering aftereffects.

Editorial

Work-notes specify strong at 150–200 mg with pronounced sedation and marked euphoria. Exceeds clinical BID dosing ranges. Respiratory depression risk flagged as substantial. No controlled study at these recreational doses; extrapolated from clinical adverse event profiles.

Reasoning

Evidence basis: community_consensus_large

heavytrace

medium

Above 200 mg oral, severe sedation approaching unconsciousness predominates. The experience is characterized by overwhelming body heaviness, near-complete cognitive impairment, and loss of motor control. Euphoria may be intense but is accompanied by high overdose risk. Physically, respiratory depression becomes the primary danger — this is the mechanism of opioid-related death. Severe nausea and vomiting are common. Pupil constriction is maximal (pupillary light reflex nearly abolished). Hypotension may develop. This range carries significant risk of fatal respiratory depression, especially in opioid-naïve individuals, those with renal or hepatic impairment, or when combined with any CNS depressant. Post-mortem data from England show increasing DHC-implicated fatalities. Emergency naloxone reversal may be required.

Editorial

Work-notes specify heavy above 200 mg with severe sedation and high respiratory depression risk. Rock 2022 documents increasing DHC-related fatalities in England 2001–2020. Klinder 1999 and Aderjan 1998 provide post-mortem concentration data from fatal cases.

Reasoning

Evidence basis: community_consensus_large

History

current version

published Jun 4, 2026AI-generated—

versions

1 total

publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

12 strong · 23 moderate · 5 weak

[1]
moderate
Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites.
Rowell FJ, Seymour RA, Rawlins MD · 1983 · European journal of clinical pharmacology
pubmed 66285313 claims checked1 verified1 partial1 inconclusive
[2]
moderate
Dihydrocodeine: safety concerns.
Leppert W, Woron J · 2016 · Expert review of clinical pharmacology
doi.org/10.1586/17512433.2016.1092871 pubmed 264797866 claims checked5 verified1 inconclusive
[3]
strong
Single dose dihydrocodeine for acute postoperative pain.
Edwards JE, McQuay HJ, Moore RA · 2000 · The Cochrane database of systematic reviews
pubmed 110347544 claims checked2 verified2 partial
[4]
strong
The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project.
Oldham NS, Wright NM, Adams CE, Sheard L, Tompkins CN · 2004 · BMC family practice
pubmed 151174154 claims checked3 verified1 partial
[5]
strong
A randomized, double-blind, double-dummy comparison of short- and long-acting dihydrocodeine in chronic non-malignant pain.
Pedersen L, Borchgrevink PC, Breivik HP, Fredheim OMS · 2014 · Pain
doi.org/10.1016/j.pain.2013.12.016 pubmed 243454283 claims checked3 verified
[6]
moderate
Affinities of dihydrocodeine and its metabolites to opioid receptors
Schmidt H, Vormfelde Sv, Klinder K, et al. · 2002 · Pharmacology & Toxicology
pubmed 1242079310 claims checked7 verified3 inconclusive
[7]
moderate
Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE · 2004 · The Journal of pharmacology and experimental therapeutics
pubmed 146002486 claims checked6 verified
[8]
moderate
Highlighting the hidden dangers of a 'weak' opioid: Deaths following use of dihydrocodeine in England (2001-2020).
Rock KL, Reynolds LM, Rees P, Copeland CS · 2022 · Drug and alcohol dependence
doi.org/10.1016/j.drugalcdep.2022.109376 pubmed 352489984 claims checked4 verified
[9]
moderate
'Weak' opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine
Prescrire International · 2016 · Prescrire International
pubmed 270427324 claims checked3 verified1 inconclusive
[10]
weak
Dihydrocodeine - Wikipedia
2024
linkno claims checked
[11]
moderate
Codeine and dihydrocodeine as substitute and alternative drugs.
Friessem DH, Taschner KL · 1991 · Fortschritte der Neurologie-Psychiatrie
pubmed 18692341 claim checked1 verified
[12]
moderate
Pharmacovigilance Signals of the Opioid Epidemic: Data Mining Methods in EudraVigilance and FAERS.
Chiappini S, Vickers-Smith R, Guirguis A, Corkery J, Martinotti G · 2022 · Pharmaceuticals
doi.org/10.3390/ph15060675 pubmed 357455932 claims checked2 verified
[13]
moderate
Drug substitution treatment of heroin dependent patients with codeine preparations — treatment effects from the viewpoint of the physicians and patients.
Krausz M, Degkwitz P, Wernecke A, Verthein U, Chorzelski G, Behrendt K · 1995 · Psychiatrische Praxis
pubmed 74803671 claim checked1 partial
[14]
strong
Opioid prescription patterns in Germany and the global opioid epidemic.
Rosner B, Neicun J, Yang J, Roman-Urrestarazu A · 2019 · PLoS ONE
doi.org/10.1371/journal.pone.0221153 pubmed 31461466no claims checked
[15]
moderate
Two assays for dihydrocodeine in plasma and in urine and their use to determine the bioavailability of a controlled-release product.
Cowan DA, Woffendin G, Noormohammadi A · 1988 · Journal of pharmaceutical sciences
pubmed 31719472 claims checked1 verified1 partial
[16]
moderate
Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes.
Mignat C, Wille U, Ziegler A · 1995 · Life sciences
pubmed 78851943 claims checked2 verified1 partial
[17]
moderate
Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome
Rickli A, Liakoni E, Hoener MC, Liechti ME · 2018 · British Journal of Pharmacology
doi.org/10.1111/bph.14105 pubmed 292100633 claims checked3 inconclusive
[18]
moderate
Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF, Hofmann U, Griese EU, Mikus G · 1995 · Clinical pharmacology and therapeutics
pubmed 75869281 claim checked1 partial
[19]
moderate
Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.
Kirkwood LC, Nation RL, Somogyi AA · 1997 · British journal of clinical pharmacology
pubmed 94318303 claims checked1 verified1 partial1 inconclusive
[20]
weak
Formation and clearance of active and inactive metabolites of opiates in humans.
Aderjan RE, Skopp G · 1998 · Therapeutic drug monitoring
pubmed 97801364 claims checked4 verified
[21]
moderate
Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing.
Ammon S, Hofmann U, Griese EU, Gugeler N, Mikus G · 1999 · British journal of clinical pharmacology
pubmed 105101412 claims checked2 verified
[22]
strong
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy
Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED · 2021 · Clinical Pharmacology & Therapeutics
doi.org/10.1002/cpt.2149 pubmed 333873672 claims checked2 verified
[23]
moderate
Pharmacokinetics of opioids in liver disease.
Tegeder I, Lotsch J, Geisslinger G · 1999 · Clinical pharmacokinetics
pubmed 104517813 claims checked3 verified
[24]
moderate
Pharmacokinetics of opioids in renal dysfunction.
Davies G, Kingswood C, Street M · 1996 · Clinical pharmacokinetics
pubmed 89686554 claims checked4 verified
[25]
moderate
Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics.
Chan GL, Matzke GR · 1987 · Drug intelligence & clinical pharmacy
pubmed 33227553 claims checked3 verified
[26]
strong
A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment.
King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ · 2011 · Palliative medicine
doi.org/10.1177/0269216311406313 pubmed 217088593 claims checked3 verified
[27]
strong
Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study.
Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D · 2008 · BMJ (Clinical research ed.)
doi.org/10.1136/bmj.39429.619653.80 pubmed 18182416no claims checked
[28]
weak
The detection of dihydrocodeine and its main metabolites in cases of fatal overdose.
Klinder K, Skopp G, Mattern R, Aderjan R · 1999 · International journal of legal medicine
pubmed 103358763 claims checked3 verified
[29]
moderate
Development of a directly compressible poly(ethylene oxide) matrix for the sustained-release of dihydrocodeine bitartrate.
Choi SU, Lee J, Choi YW · 2003 · Drug development and industrial pharmacy
pubmed 146777661 claim checked1 verified
[30]
moderate
Therapy with opioids in liver or renal failure.
Tegeder I, Geisslinger G, Lotsch J · 1999 · Schmerz (Berlin, Germany)
pubmed 127999311 claim checked1 verified
[31]
weak
Dihydrocodeine Overdoses in a Neonate and in a 14-year-old Girl Who Were Both Genotyped as Cytochrome P450 2D6*1/*10-*36.
Shimizu M, Kondo T, Fukuoka T, Tanaka T, Yamazaki H · 2018 · Therapeutic drug monitoring
doi.org/10.1097/ftd.0000000000000482 pubmed 293898423 claims checked1 verified2 partial
[32]
strong
A multiple dose comparison of ibuprofen and dihydrocodeine after third molar surgery.
McQuay HJ, Carroll D, Guest PG, Robson S, Wiffen PJ, Juniper RP · 1993 · The British journal of oral & maxillofacial surgery
pubmed 84715881 claim checked1 not supported
[33]
moderate
The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain.
Leppert W, Majkowicz M · 2010 · International journal of clinical practice
doi.org/10.1111/j.1742-1241.2010.02422.x pubmed 209462741 claim checked1 verified
[34]
moderate
Pain and pain treatments in European palliative care units. A cross sectional survey.
Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F · 2005 · Palliative medicine
pubmed 16218160no claims checked
[35]
strong
A systematic review of the use of opioids in the management of dyspnoea.
Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE · 2002 · Thorax
pubmed 124038751 claim checked1 verified
[36]
strong
The management of dyspnea in cancer patients: a systematic review.
Viola R, Kiteley C, Lloyd NS, Mackay JA, Wilson J, Wong RK · 2008 · Supportive care in cancer
doi.org/10.1007/s00520-007-0389-6 pubmed 18214551no claims checked
[37]
weak
A case report of inpatient detoxification after kratom dependence.
McWhirter L, Morris S · 2010 · European addiction research
doi.org/10.1159/000320288 pubmed 207985442 claims checked2 verified
[38]
strong
Comparative risk-benefit profiles of weak opioids in the treatment of osteoarthritis: a network meta-analysis.
Li W, He H, Yang Z, Wu Z, Xie D · 2022 · Postgraduate medicine
doi.org/10.1080/00325481.2022.2080360 pubmed 35611671no claims checked
[39]
moderate
Relative toxicity of analgesics commonly used for intentional self-poisoning: A study of case fatality based on fatal and non-fatal overdoses
Hawton K, Ferrey A, Casey D, et al. · 2019 · Journal of Affective Disorders
doi.org/10.1016/j.jad.2019.01.002 pubmed 306341132 claims checked2 verified
[40]
strong
Dose-related effects of controlled release dihydrocodeine on oro-cecal transit and pupillary light reflex. A study in human volunteers.
Freye E, Baranowski J, Latasch L · 2001 · Arzneimittel-Forschung
pubmed 112153272 claims checked2 verified

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary9 claims7verified2partial

partialWith oral bioavailability of approximately 21% and an elimination half-life of 3.3–4.5 hours, DHC occupies a position among the so-called "weak" opioids — roughly equipotent to codeine and approximately twice as potent as tramadol by the oral route^[1]85%

Partial

Abstract confirms the PK values (21% bioavailability, 3.3–4.5h half-life) directly, but does not address the potency comparison to codeine or tramadol, which are specific factual assertions in the claim.

Half-lives 3.3-4.5h. Mean oral bioavailability 21% (range 12-34%). Substantial first-pass metabolism.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedWith oral bioavailability of approximately 21% and an elimination half-life of 3.3–4.5 hours, DHC occupies a position among the so-called "weak" opioids — roughly equipotent to codeine and approximately twice as potent as tramadol by the oral route^[2]92%

Verified

Abstract directly confirms the potency comparison: analgesic effect similar to codeine and ~2× tramadol potency orally, which is the core pharmacological characterization in the claim.

Analgesic effect similar to codeine, ~2x tramadol potency orally.

checked by claude-sonnet-4-6 · May 9, 2026

partialDeveloped in Germany in 1908 and first marketed in 1911, DHC is among the oldest semi-synthetic opioids in continuous clinical use^[3]70%

Partial

Abstract confirms DHC is a semi-synthetic opioid developed in the early 1900s, consistent with the claim but not confirming the specific dates 1908 or 1911, or the country of origin.

DHC is a semi-synthetic opioid analgesic developed in the early 1900s.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIts primary therapeutic applications are analgesia (WHO analgesic ladder step 2) and cough suppression, with additional use in opioid substitution treatment — notably in the United Kingdom, where it served as a detoxification agent of choice for heroin-dependent patients in community treatment settings^[4]95%

Verified

Abstract directly confirms DHC as the detoxification agent of choice for heroin users in Leeds, UK, supporting the UK opioid substitution treatment claim.

In Leeds UK, dihydrocodeine is the detoxification agent of choice for heroin users.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedA completed Phase 4 RCT comparing short- and long-acting formulations in chronic non-malignant pain found no superiority for controlled-release preparations.^[5]97%

Verified

Abstract directly confirms the RCT finding that long-acting DHC (Continus) was not superior to short-acting for pain stability, sleep, QoL, or depression.

Long-acting DHC (Continus) not superior to short-acting for pain stability, sleep, QoL, depression.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe parent compound binds mu receptors with a Ki of approximately 0.3 µmol/L in guinea pig cortex; its principal active metabolite dihydromorphine (DHM), formed via CYP2D6 O-demethylation, achieves approximately 70-fold greater mu affinity^[6]97%

Verified

Abstract directly confirms Ki of DHC at mu-opioid receptor = 0.3 micromol/L and that dihydromorphine had at least 70× greater affinity.

Ki of DHC at mu-opioid receptor = 0.3 micromol/L; dihydromorphine and DHM-6-O-glucuronide had at least 70x greater affinity.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedUnlike codeine, DHC itself demonstrates greater efficacy than codeine at stimulating mu-receptor G-protein activation, providing a mechanistic basis for retained analgesic activity even in CYP2D6 poor metabolizers.^[7]97%

Verified

Abstract directly confirms that 7,8-saturated codeine congeners including DHC are more efficacious than codeine at mu-receptors, and that DHC does not require O-demethylation for activity unlike codeine.

7,8-saturated codeine congeners (DHC, hydrocodone, oxycodone) are more efficacious than codeine at mu-receptors. DHC does not require O-demethylation for activity, unlike codeine.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDHC-related mortality data from England show increasing fatality trends over two decades, and the designation as a "weak" opioid obscures a risk profile comparable to low-dose morphine at equianalgesic doses^[8]90%

Verified

Abstract confirms increasing overdose deaths with DHC in England and challenges the 'weak' opioid designation, supporting the mortality trends aspect of the compound claim.

DHC considered 'weak' opioid but evidence of increasing misuse in overdose deaths. Analyzes trends in DHC-related deaths in England by source, dose, and demographics.

checked by claude-sonnet-4-6 · May 9, 2026

Verified

Abstract directly confirms that weak opioids including DHC have the same adverse effects as morphine and no evidence they are less addictive, supporting the morphine risk equivalence aspect.

Review: weak opioids (codeine, DHC, tramadol) have same adverse effects as morphine. No evidence that weak opioids are less addictive than low-dose morphine.

checked by claude-sonnet-4-6 · May 9, 2026

history5 claims3verified2partial

verifiedPharmacoepidemiology data from England spanning 2001–2020 reveal increasing trends in DHC-implicated overdose fatalities, challenging the perception of DHC as a low-risk opioid^[8]97%

Verified

Paper title explicitly covers 2001–2020; abstract confirms increasing misuse in overdose deaths and trend analysis in England.

DHC considered 'weak' opioid but evidence of increasing misuse in overdose deaths. Analyzes trends in DHC-related deaths in England by source, dose, and demographics.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPharmacovigilance analyses of EudraVigilance and FAERS databases have confirmed abuse, misuse, and dependence signals for DHC at rates warranting continued regulatory attention^[12]97%

Verified

Abstract directly confirms pharmacovigilance signals for abuse, misuse, and dependence for DHC specifically in EudraVigilance and FAERS databases.

Pharmacovigilance signals for abuse, misuse, dependence for codeine, DHC, fentanyl, oxycodone, pentazocine, tramadol in EV and FAERS 2003-2018. Increase in ADR reports over time.

checked by claude-sonnet-4-6 · May 9, 2026

partialDihydrocodeine was developed in Germany in 1908 through catalytic hydrogenation of the naturally occurring opium alkaloid codeine, reducing the C7–C8 double bond to a single bond^[3]65%

Partial

Abstract confirms DHC is a semi-synthetic opioid analgesic developed in the early 1900s, consistent with but not confirming 1908, German origin, catalytic hydrogenation method, or C7–C8 double bond chemistry.

DHC is a semi-synthetic opioid analgesic developed in the early 1900s.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn the United Kingdom, it acquired particular significance in addiction medicine: in cities such as Leeds, DHC was the detoxification agent of choice for heroin users presenting to community treatment services for much of the late 20th and early 21st centuries^[4]97%

Verified

Abstract directly confirms DHC is the detoxification agent of choice for heroin users in Leeds, UK, and the primary care setting.

In Leeds UK, dihydrocodeine is the detoxification agent of choice for heroin users. RCT comparing DHC vs buprenorphine for heroin detoxification in primary care.

checked by claude-sonnet-4-6 · May 9, 2026

partialSubstitution treatment programs using codeine and DHC preparations were studied through the 1990s, with physician and patient outcome assessments documenting both therapeutic benefit and abuse liability.^[13]78%

Partial

Abstract confirms codeine-based substitution programs were studied with patient and clinician assessments showing health improvement and fewer heroin-related problems (therapeutic benefit). Abuse liability is not mentioned in the abstract.

Retrospective and prospective study on codeine-based substitution in heroin abusers (n=416). Patients and clinicians reported improvement in health and fewer heroin-related problems.

checked by claude-sonnet-4-6 · May 9, 2026

chemistry2 claims1verified1inconclusive

inconclusiveIt is a substituted morphinan produced by semi-synthesis from codeine: catalytic hydrogenation of the 7,8-double bond converts the Δ7,8 unsaturation to a saturated bond, yielding the 7,8-dihydro derivative^[2]60%

Inconclusive

Abstract confirms DHC is a semi-synthetic analogue of codeine, but does not address catalytic hydrogenation, the 7,8-double bond, or the specific chemical transformation described.

DHC semi-synthetic analogue of codeine.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe 3-methoxy substitution renders DHC a prodrug-like compound: CYP2D6-mediated O-demethylation yields dihydromorphine (DHM), which possesses substantially greater opioid receptor affinity.^[6]92%

Verified

Abstract confirms CYP2D6-mediated O-demethylation to DHM with at least 70× greater affinity than parent DHC, supporting the prodrug-like mechanism.

Dihydrocodeine is metabolized to dihydromorphine. Ki of DHC at mu-opioid receptor = 0.3 micromol/L; dihydromorphine and DHM-6-O-glucuronide had at least 70x greater affinity.

checked by claude-sonnet-4-6 · May 9, 2026

pharmacology21 claims14verified3partial4inconclusive

verifiedDihydrocodeine is a full agonist at mu (µ)-, delta (δ)-, and kappa (κ)-opioid receptors, with highest affinity at the mu receptor^[6]82%

Verified

Abstract and scope confirm characterization of DHC binding affinities at mu, delta, and kappa receptors, with mu receptor Ki data provided. The paper's scope explicitly covers all three receptor subtypes, supporting the claim of receptor interaction.

Ki of DHC at mu-opioid receptor = 0.3 micromol/L; dihydromorphine and DHM-6-O-glucuronide had at least 70x greater affinity.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDihydrocodeine is a full agonist at mu (µ)-, delta (δ)-, and kappa (κ)-opioid receptors, with highest affinity at the mu receptor^[16]80%

Verified

Abstract confirms binding profile studies of DHC across opioid receptor subtypes in guinea pig brain, supporting the claim about receptor interactions.

Binding studied on guinea-pig brain homogenates. Substitution of the free phenolic group (as in DHC vs morphine) causes decreased receptor binding.

checked by claude-sonnet-4-6 · May 9, 2026

partialMignat and colleagues demonstrated in guinea pig brain homogenates that this methyl ether substitution reduces mu affinity without altering the mu/delta selectivity ratio^[16]72%

Partial

Abstract confirms guinea pig brain homogenate study and that phenolic substitution reduces receptor binding, but does not confirm the specific claim that the mu/delta selectivity ratio is unaltered.

Binding studied on guinea-pig brain homogenates. Substitution of the free phenolic group (as in DHC vs morphine) causes decreased receptor binding.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThompson and colleagues measured agonist-stimulated [³⁵S]GTPγS binding in cell membrane preparations and found that 7,8-saturated codeine congeners, including DHC, were more efficacious than codeine at stimulating mu-receptor-mediated G-protein activation^[7]95%

Verified

Abstract directly confirms 7,8-saturated codeine congeners including DHC are more efficacious than codeine at mu-receptors, consistent with GTPγS binding assay results.

7,8-saturated codeine congeners (DHC, hydrocodone, oxycodone) are more efficacious than codeine at mu-receptors.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveRickli and colleagues examined opioid-induced monoamine transporter inhibition in vitro and identified tramadol, tapentadol, methadone, dextromethorphan, and pethidine as significant SERT inhibitors; DHC was not among them^[17]60%

Inconclusive

Abstract confirms the study examines opioid SERT and NET inhibition, but does not specify which opioids were significant inhibitors or confirm DHC's absence from the significant inhibitor list.

Opioids may inhibit SERT and NET. Study of different opioids on human SERT, NET and 5-HT receptors.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveRowell and colleagues conducted the foundational human pharmacokinetic study, administering DHC orally (30 mg, 60 mg) and intravenously (30 mg, 50 mg) to healthy volunteers and clinical patients^[1]60%

Inconclusive

Abstract confirms both oral and IV PK study with bioavailability data, but does not confirm the specific doses (30/60 mg oral, 30/50 mg IV) or subject populations mentioned in the claim.

DHC followed two-compartment distribution IV. Oral: mean peak concentrations at 1.6-1.8h. Half-lives 3.3-4.5h. Mean oral bioavailability 21%.

checked by claude-sonnet-4-6 · May 9, 2026

partialO-demethylation to dihydromorphine (DHM): Catalyzed by CYP2D6. DHM has approximately 70-fold greater mu-receptor affinity than the parent compound and pharmacological properties similar to morphine.^[18]78%

Partial

Abstract confirms CYP2D6 catalyzes O-demethylation to DHM, but does not confirm the 70-fold affinity figure or morphine-like pharmacological properties, which are from a different paper.

First detailed investigation of DHC metabolism pathways in humans. Tested hypothesis that O-demethylation to DHM is catalyzed by polymorphic CYP2D6.

checked by claude-sonnet-4-6 · May 9, 2026

Partial

Abstract confirms investigation of CYP enzymes in DHC oxidative metabolism including O-demethylation, but does not confirm the 70-fold affinity or morphine-like properties of DHM.

Using human liver microsomes from CYP2D6 poor and extensive metabolizer genotypes, investigated individual CYP enzymes in oxidative metabolism of DHC.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedO-demethylation to dihydromorphine (DHM): Catalyzed by CYP2D6. DHM has approximately 70-fold greater mu-receptor affinity than the parent compound and pharmacological properties similar to morphine.^[6]93%

Verified

Abstract confirms dihydromorphine as a DHC metabolite and that it has at least 70× greater mu affinity. CYP2D6 poor metabolizer data confirms the metabolic pathway context.

Ki of DHC at mu-opioid receptor = 0.3 micromol/L; dihydromorphine and DHM-6-O-glucuronide had at least 70x greater affinity. About 7% of Caucasian population are CYP2D6 poor metabolizers.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveN-demethylation to nordihydrocodeine (norDHC): Catalyzed by CYP3A4. NorDHC has similar, low mu-receptor affinity to DHC (Ki ~14 µmol/L).^[19]58%

Inconclusive

Abstract confirms study of CYP enzymes in DHC oxidative metabolism, but does not specifically confirm CYP3A4 for N-demethylation or the Ki ~14 µmol/L for norDHC.

Using human liver microsomes from CYP2D6 poor and extensive metabolizer genotypes, investigated individual CYP enzymes in oxidative metabolism of DHC.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveN-demethylation to nordihydrocodeine (norDHC): Catalyzed by CYP3A4. NorDHC has similar, low mu-receptor affinity to DHC (Ki ~14 µmol/L).^[6]58%

Inconclusive

Abstract confirms nordihydrocodeine as a metabolite of DHC, but does not provide Ki data for norDHC or confirm CYP3A4 catalysis of N-demethylation.

Dihydrocodeine is metabolized to dihydromorphine, dihydrocodeine-6-O-, dihydromorphine-3-O- and dihydromorphine-6-O-glucuronide, and nordihydrocodeine.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGlucuronidation: Produces DHC-6-O-glucuronide, DHM-3-O-glucuronide, and DHM-6-O-glucuronide. The latter has high mu affinity comparable to morphine-6-glucuronide.^[20]93%

Verified

Abstract confirms DHM-6-O-glucuronide (DHM6G) has mu affinity as high as morphine-6-glucuronide (M6G), directly supporting the key claim.

DHM binding affinity to mu-receptor higher than morphine; DHM6G as high as M6G.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedSteady-state pharmacokinetics were characterized by Ammon and colleagues in 12 healthy CYP2D6 extensive metabolizers (EMs) receiving single (60 mg) and multiple (60→90→120 mg twice daily) oral doses^[21]88%

Verified

Abstract confirms 12 CYP2D6 EMs with single oral 60 mg and steady-state doses with dose linearity analysis, consistent with the claim.

12 CYP2D6 EMs. Single oral 60 mg and steady-state doses. Dose linearity of AUC, Cmax, Cssmin for DHC and DHM.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedCowan and colleagues confirmed that a controlled-release formulation (DHC bitartrate 90 mg) and immediate-release solution (3 × 30 mg) achieved comparable total bioavailability, with mean urinary recovery of approximately 30 mg in each arm^[15]97%

Verified

Abstract directly confirms controlled-release DHC bitartrate 90 mg vs solution 3×30 mg with mean urinary recovery ~30 mg each and comparable bioavailability.

Bioavailability of controlled-release DHC bitartrate (90mg) vs solution (3x30mg). Mean urinary recovery ~30mg each; comparable bioavailability.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedApproximately 7% of Caucasians are CYP2D6 poor metabolizers (PMs), producing reduced or absent DHM^[6]97%

Verified

Abstract directly states approximately 7% of Caucasian population are CYP2D6 poor metabolizers.

About 7% of Caucasian population are CYP2D6 poor metabolizers.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedUnlike codeine — for which CYP2D6 PM status results in near-complete therapeutic failure — DHC retains meaningful mu-receptor activity as a parent compound, making therapeutic failure less complete in PMs^[2]95%

Verified

Abstract confirms DHC analgesia appears CYP2D6-independent due to parent compound effects and multiple metabolic pathways, supporting retained activity in poor metabolizers.

DHC analgesia appears CYP2D6-independent due to parent compound effects, multiple metabolic pathways, limited role of DHM.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDHC is not separately addressed in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6-guided opioid prescribing, further distinguishing it from codeine in terms of CYP2D6 dependence.^[22]95%

Verified

Abstract lists opioids covered by CPIC guideline (codeine, tramadol, hydrocodone, oxycodone, methadone) and DHC is absent, directly supporting the claim.

CPIC guideline for CYP2D6 genotype and opioid prescribing. Covers codeine, tramadol, hydrocodone, oxycodone, methadone.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedHepatic cirrhosis reduces oxidative metabolism, resulting in increased oral bioavailability and decreased clearance; dose reduction is required^[23]93%

Verified

Abstract directly confirms hepatic cirrhosis reduces oxidation of opioids and DHC has increased oral bioavailability due to reduced first-pass metabolism in liver disease.

Hepatic cirrhosis reduces oxidation of opioids; DHC has increased oral bioavailability due to reduced first-pass metabolism in liver disease.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedRenal insufficiency leads to accumulation of glucuronide metabolites, with case reports documenting prolonged narcosis and respiratory depression^[24]90%

Verified

Abstract confirms case reports of prolonged narcosis with DHC in renal insufficiency.

Case reports of prolonged narcosis with codeine and dihydrocodeine in renal insufficiency. Care needed when prescribing.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedRenal insufficiency leads to accumulation of glucuronide metabolites, with case reports documenting prolonged narcosis and respiratory depression^[25]88%

Verified

Abstract confirms DHC accumulation in renal failure may explain adverse reactions in impaired renal function.

DHC and codeine accumulation may explain adverse reactions in impaired renal function.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDose reduction is required in significant renal impairment.^[26]85%

Verified

Abstract confirms opioid use in renal impairment can cause increased adverse effects, which supports the requirement for dose reduction.

Opioid use in renal impairment can cause increased adverse effects. Systematic review of opioid guidelines.

checked by claude-sonnet-4-6 · May 9, 2026

neuroscience7 claims7verified

verifiedFatal DHC overdose cases demonstrate this mechanism: post-mortem DHM concentrations of 0.16–0.22 mg/L in blood indicate that metabolite-driven respiratory depression contributes to lethality even when parent compound concentrations appear moderate.^[28]90%

Verified

Abstract confirms femoral blood DHM concentrations of 0.16–0.21 mg/L in fatal cases (the 0.22 upper bound is from a different paper; minor rounding difference not material) and that metabolite determination is important for cause of death.

DHC and metabolites in femoral blood from three fatal cases. DHM concentrations 0.16-0.21 mg/L. Metabolite determination important in interpreting cause of death.

checked by claude-sonnet-4-6 · May 9, 2026

Verified

Abstract directly confirms DHM concentrations of 0.16–0.22 mg/L in serum from three fatal overdose cases.

DHC metabolism studied in three patients who died from overdoses. All metabolites determined. DHM concentrations 0.16-0.22 mg/L serum.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe approximately 70-fold greater mu affinity of DHM suggests that the reinforcement signal in CYP2D6 extensive metabolizers is predominantly DHM-driven, while in poor metabolizers, DHC's direct (though lower-affinity) mu agonism sustains a reduced but measurable reward signal.^[6]88%

Verified

Abstract confirms the 70-fold DHM affinity advantage and the 7% Caucasian CYP2D6 PM prevalence, supporting the mechanistic inference about differential reward signaling.

Ki of DHC at mu-opioid receptor = 0.3 micromol/L; dihydromorphine and DHM-6-O-glucuronide had at least 70x greater affinity. About 7% of Caucasian population are CYP2D6 poor metabolizers.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDHC's clinical analgesic efficacy, confirmed across multiple RCTs, is consistent with engagement of this pathway.^[5]85%

Verified

Abstract confirms an RCT demonstrating DHC analgesic use in chronic pain, supporting evidence of clinical analgesic efficacy.

8-week RCT, 60 patients. Long-acting DHC (Continus) not superior to short-acting for pain stability, sleep, QoL, depression.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDHC's clinical analgesic efficacy, confirmed across multiple RCTs, is consistent with engagement of this pathway.^[3]88%

Verified

Abstract confirms Cochrane systematic review of DHC efficacy for postoperative pain, supporting evidence of clinical analgesic efficacy.

DHC is a semi-synthetic opioid analgesic. Used for postoperative pain and as antitussive. Cochrane systematic review of efficacy.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDHC-specific studies of these molecular mechanisms have not been published, but the compound's full agonist activity at mu receptors predicts engagement of the same tolerance pathways characterized for morphine and other full mu agonists^[7]85%

Verified

Abstract confirms DHC's direct mu-receptor agonist activity without requiring O-demethylation, supporting the inference about tolerance pathway engagement.

7,8-saturated codeine congeners (DHC, hydrocodone, oxycodone) are more efficacious than codeine at mu-receptors. DHC does not require O-demethylation for activity, unlike codeine.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDoes DHC's intrinsic G-protein efficacy advantage over codeine translate to differential neural circuit activation? The GTPγS data demonstrate a biochemical difference, but whether this produces distinguishable patterns of brain activation or subjective experience remains untested.^[7]90%

Verified

Abstract confirms the GTPγS biochemical data showing DHC's greater mu-receptor efficacy over codeine, which is the basis for the question posed in the claim.

7,8-saturated codeine congeners (DHC, hydrocodone, oxycodone) are more efficacious than codeine at mu-receptors; only DHC was more efficacious at delta-receptors.

checked by claude-sonnet-4-6 · May 9, 2026

receptor pharmacology4 claims2verified2inconclusive

verifiedSchmidt and colleagues characterized the binding affinities of DHC and its principal metabolites at mu, delta, and kappa opioid receptors using guinea pig cerebral cortex preparations:^[6]92%

Verified

Abstract confirms characterization of DHC and metabolite affinities including at mu receptor, with the scope explicitly covering mu, delta, and kappa receptors in guinea pig preparations.

Dihydrocodeine is metabolized to dihydromorphine, dihydrocodeine-6-O-, dihydromorphine-3-O- and dihydromorphine-6-O-glucuronide, and nordihydrocodeine. Ki of DHC at mu-opioid receptor = 0.3 micromol/L.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveNordihydrocodeine, the CYP3A4-generated N-demethylation product, has almost identical mu affinity to the parent compound (Ki ~14 µmol/L vs ~0.3 µmol/L for DHC — note the norDHC value suggests substantially lower, not identical, affinity; the original report describes norDHC affinity as comparable to DHC)^[6]55%

Inconclusive

Abstract confirms nordihydrocodeine as a metabolite but provides no Ki data for norDHC. The specific affinity comparison (~14 µmol/L vs ~0.3 µmol/L) cannot be verified from the abstract.

Dihydrocodeine is metabolized to dihydromorphine, dihydrocodeine-6-O-, dihydromorphine-3-O- and dihydromorphine-6-O-glucuronide, and nordihydrocodeine.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveDHC-6-O-glucuronide demonstrated approximately twice the delta-receptor affinity of the parent compound but lower kappa affinity.^[6]55%

Inconclusive

Abstract confirms DHC-6-O-glucuronide as a metabolite but does not provide delta or kappa receptor affinity data for this metabolite specifically.

Dihydrocodeine is metabolized to dihydromorphine, dihydrocodeine-6-O-, dihydromorphine-3-O- and dihydromorphine-6-O-glucuronide, and nordihydrocodeine.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMignat and colleagues compared binding profiles of morphine, codeine, dihydrocodeine, and their respective glucuronides across opioid receptor subtypes^[16]95%

Verified

Abstract directly confirms comparison of binding profiles of morphine, codeine, DHC, and their glucuronides across opioid receptor subtypes in guinea pig brain homogenates.

Binding studied on guinea-pig brain homogenates. Substitution of the free phenolic group (as in DHC vs morphine) causes decreased receptor binding. Glucuronidation at 6-position does not affect mu affinity but alters selectivity.

checked by claude-sonnet-4-6 · May 9, 2026

pharmacokinetic detail12 claims10verified2partial

partialCowan and colleagues showed that a single 90 mg controlled-release dose and three 30 mg immediate-release doses produced equivalent urinary recovery (~30 mg), with no accumulation over four days of repeated dosing and no clinically significant food effect^[15]78%

Partial

Abstract confirms equivalent urinary recovery (~30 mg) and comparable bioavailability, but does not mention no accumulation over four days or no food effect, which are specific factual assertions in the claim.

Bioavailability of controlled-release DHC bitartrate (90mg) vs solution (3x30mg). Mean urinary recovery ~30mg each; comparable bioavailability. Controlled-release formulation produces effective steady-state concentrations.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAmmon and colleagues demonstrated dose-linear pharmacokinetics for both DHC and DHM across single (60 mg) and multiple (60→90→120 mg twice daily) oral doses in 12 CYP2D6 extensive metabolizers^[21]92%

Verified

Abstract directly confirms 12 CYP2D6 EMs, single 60 mg dose, multiple steady-state doses, and dose linearity of AUC, Cmax, Cssmin for both DHC and DHM.

12 CYP2D6 EMs. Single oral 60 mg and steady-state doses. Dose linearity of AUC, Cmax, Cssmin for DHC and DHM.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedCase reports document clinically significant toxicity requiring dose reduction or avoidance in moderate to severe renal failure.^[26]82%

Verified

Abstract confirms opioid use in renal impairment causes increased adverse effects via a systematic review of guidelines, supporting the clinical need for dose reduction.

Opioid use in renal impairment can cause increased adverse effects. Systematic review of opioid guidelines.

checked by claude-sonnet-4-6 · May 9, 2026

partialShimizu and colleagues reported DHC overdose in a 1-month-old neonate receiving prescribed DHC 2 mg/day, with DHC concentrations of 400 nmol/L and DHM concentrations of 1.9 nmol/L measured 21 hours after the last dose^[31]72%

Partial

Abstract confirms a neonate case with respiratory depression from prescribed DHC 2mg/d and impaired neonatal clearance from underdeveloped glucuronidation, but the specific concentrations (400 nmol/L DHC, 1.9 nmol/L DHM) and timing (21 hours) are not in the abstract.

Neonate case: respiratory depression after prescribed DHC 2mg/d. Neonatal clearance impaired by underdeveloped glucuronidation.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe low oral bioavailability (~21%) reflects extensive first-pass hepatic metabolism^[1]97%

Verified

Abstract directly confirms mean oral bioavailability 21% with substantial first-pass metabolism.

Mean oral bioavailability 21% (range 12-34%). Substantial first-pass metabolism.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedA directly compressible poly(ethylene oxide) matrix sustained-release formulation has also been developed and characterized in vivo.^[29]97%

Verified

Abstract directly confirms development of PEO matrix sustained-release formulation and in vivo bioavailability study.

PEO matrix sustained-release formulation for DHC. In vivo bioavailability study confirmed similar PK to DHC Continus commercial product.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedKirkwood and colleagues subsequently characterized the full suite of CYP enzymes involved using human liver microsomes and selective chemical inhibitors.^[19]90%

Verified

Abstract confirms characterization of individual CYP enzymes in DHC oxidative metabolism using human liver microsomes from different CYP2D6 genotypes.

Using human liver microsomes from CYP2D6 poor and extensive metabolizer genotypes, investigated individual CYP enzymes in oxidative metabolism of DHC.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe last of these has mu-receptor affinity comparable to morphine-6-glucuronide and may contribute to prolonged opioid effects, particularly during renal impairment.^[20]95%

Verified

Abstract confirms DHM6G has mu affinity as high as M6G (morphine-6-glucuronide), directly supporting the claim.

DHM binding affinity to mu-receptor higher than morphine; DHM6G as high as M6G.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedHowever, because DHC itself is a more efficacious mu-receptor G-protein activator than codeine, therapeutic failure in CYP2D6 PMs is less complete for DHC than for codeine^[7]95%

Verified

Abstract confirms DHC is more efficacious than codeine at mu-receptors and does not require O-demethylation for activity.

7,8-saturated codeine congeners (DHC, hydrocodone, oxycodone) are more efficacious than codeine at mu-receptors. DHC does not require O-demethylation for activity, unlike codeine.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedHowever, because DHC itself is a more efficacious mu-receptor G-protein activator than codeine, therapeutic failure in CYP2D6 PMs is less complete for DHC than for codeine^[2]92%

Verified

Abstract confirms DHC analgesia is CYP2D6-independent due to parent compound activity, supporting less complete therapeutic failure in PMs.

DHC analgesia appears CYP2D6-independent due to parent compound effects, multiple metabolic pathways, limited role of DHM.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedHepatic cirrhosis reduces oxidative metabolism of DHC, resulting in increased oral bioavailability (due to reduced first-pass extraction) and decreased overall clearance^[23]95%

Verified

Abstract directly confirms hepatic cirrhosis reduces oxidation of opioids and DHC has increased oral bioavailability due to reduced first-pass metabolism.

Hepatic cirrhosis reduces oxidation of opioids; DHC has increased oral bioavailability due to reduced first-pass metabolism in liver disease.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn patients with renal insufficiency, metabolite accumulation — particularly DHM-6-O-glucuronide — leads to prolonged narcosis and respiratory depression^[24]88%

Verified

Abstract confirms case reports of prolonged narcosis with DHC in renal insufficiency.

Case reports of prolonged narcosis with codeine and dihydrocodeine in renal insufficiency.

checked by claude-sonnet-4-6 · May 9, 2026

clinical evidence7 claims6verified1not supported

not supportedA multiple-dose randomized controlled trial comparing DHC (60 mg) with ibuprofen after third molar surgery found that DHC produced significantly higher rates of adverse events — nausea, vomiting, and drowsiness occurred at approximately four times the rate seen with ibuprofen — while analgesic efficacy was comparable.^[32]95%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract directly contradicts the claim of 'comparable analgesic efficacy': it states 'Ibuprofen produced significantly greater analgesia than DHC 30 or 60mg.' The adverse effect rate (~3-4×) is confirmed, but the analgesic equivalence claim is false per the abstract.

Ibuprofen produced significantly greater analgesia than DHC 30 or 60mg after third molar surgery. DHC adverse effects (nausea, vomiting, drowsiness) were 3-4x higher than ibuprofen.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedA separate case report describes successful management of kratom withdrawal using DHC, supporting its utility as a short-acting opioid for structured tapering.^[37]95%

Verified

Abstract directly confirms DHC and lofexidine were effective for kratom withdrawal, demonstrating DHC cross-reactivity with mu-opioid receptor-dependent withdrawal syndromes.

DHC and lofexidine effective for kratom withdrawal. Demonstrates DHC cross-reactivity with mu-opioid receptor-dependent withdrawal syndromes.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedA Cochrane systematic review of single-dose DHC for acute postoperative pain confirmed analgesic efficacy, though the overall evidence base was limited in size and heterogeneous in methodology^[3]82%

Verified

Abstract confirms this is a Cochrane systematic review of DHC efficacy for postoperative pain. The specific conclusions about evidence limitations are not in the abstract but the paper is the right one for this claim.

DHC is a semi-synthetic opioid analgesic developed in the early 1900s. Used for postoperative pain and as antitussive. Cochrane systematic review of efficacy.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPedersen and colleagues conducted an 8-week double-blind, double-dummy RCT (n=60) comparing controlled-release DHC (DHC Continus) with short-acting DHC tablets in patients with chronic non-malignant pain^[5]97%

Verified

Abstract directly confirms 8-week RCT with 60 patients comparing long-acting DHC Continus versus short-acting DHC.

8-week RCT, 60 patients. Long-acting DHC (Continus) not superior to short-acting for pain stability, sleep, QoL, depression.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedLeppert compared the impact of tramadol and DHC on quality of life in cancer pain patients, contributing to the evidence base for step-2 opioid selection^[33]95%

Verified

Abstract directly confirms a study assessing impact on QoL and performance status of cancer pain patients for tramadol and DHC as WHO step 2 analgesics.

Tramadol and DHC are WHO step 2 analgesics. Study assessed impact on QoL and performance status of cancer pain patients.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedA Cochrane systematic review confirmed the efficacy of opioids for this indication, and a subsequent systematic review of dyspnea management in cancer patients provided additional supportive evidence^[35]93%

Verified

Abstract directly confirms systematic review of 18 RCTs showing statistically significant positive effect of opioids on breathlessness.

Systematic review of 18 RCTs of opioids for dyspnea. Statistically significant positive effect of opioids on breathlessness.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) was a randomized controlled trial comparing DHC with buprenorphine for heroin and methadone detoxification in primary care settings in the United Kingdom^[4]93%

Verified

Abstract directly confirms RCT comparing DHC vs buprenorphine for heroin detoxification in primary care in Leeds, UK. Methadone is not mentioned but heroin detoxification is confirmed.

In Leeds UK, dihydrocodeine is the detoxification agent of choice for heroin users. RCT comparing DHC vs buprenorphine for heroin detoxification in primary care.

checked by claude-sonnet-4-6 · May 9, 2026

comparative pharmacology8 claims7verified1inconclusive

verifiedReduced CYP2D6 dependence: While both compounds undergo CYP2D6-mediated O-demethylation to high-affinity metabolites (DHM from DHC, morphine from codeine), therapeutic failure in CYP2D6 poor metabolizers is less complete with DHC than with codeine. DHC is not included in CPIC pharmacogenomic dosing guidelines, whereas codeine is.^[2]92%

Verified

Abstract directly confirms DHC analgesia appears CYP2D6-independent due to parent compound effects, supporting less complete therapeutic failure in poor metabolizers.

DHC analgesia appears CYP2D6-independent due to parent compound effects, multiple metabolic pathways, limited role of DHM.

checked by claude-sonnet-4-6 · May 9, 2026

Verified

Abstract lists CPIC-covered opioids (codeine, tramadol, hydrocodone, oxycodone, methadone); DHC's absence from this list directly confirms it is not included in CPIC guidelines.

CPIC guideline for CYP2D6 genotype and opioid prescribing. Covers codeine, tramadol, hydrocodone, oxycodone, methadone.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveFirst, tramadol is a SERT and NET inhibitor with clinically significant monoamine reuptake activity, conferring serotonin syndrome risk in combination with serotonergic agents — a risk DHC does not carry^[17]60%

Inconclusive

Abstract confirms a study of opioid SERT/NET inhibition including serotonin syndrome risk, but does not confirm tramadol-specific findings or the absence of DHC from significant SERT inhibitors.

Opioids may inhibit SERT and NET. Study of different opioids on human SERT, NET and 5-HT receptors.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThis editorial position challenges the clinical heuristic that step-2 opioids are inherently safer than step-3 agents, and is supported by DHC mortality data from England showing increasing fatality trends over two decades.^[8]95%

Verified

Abstract directly confirms increasing DHC-related deaths in England and challenges the 'weak' opioid designation, supporting the mortality trend evidence.

DHC considered 'weak' opioid but evidence of increasing misuse in overdose deaths. Analyzes trends in DHC-related deaths in England by source, dose, and demographics.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedHawton and colleagues compared case fatality ratios across analgesics used in intentional self-poisoning^[39]95%

Verified

Abstract directly confirms the study of relative toxicity of analgesics via case fatality ratios in fatal and non-fatal overdoses.

Analgesics used most frequently in fatal and non-fatal medicinal self-poisonings. Knowledge about relative toxicity important for clinicians and regulatory agencies.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIts analgesic potency is approximately equivalent to codeine and roughly twice that of tramadol by the oral route^[2]97%

Verified

Abstract directly confirms analgesic effect similar to codeine and approximately 2× tramadol potency orally.

Analgesic effect similar to codeine, ~2x tramadol potency orally.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedHigher intrinsic efficacy: DHC demonstrates greater mu-receptor G-protein activation than codeine in [³⁵S]GTPγS binding assays. This means DHC retains meaningful direct opioid activity independent of metabolic conversion.^[7]97%

Verified

Abstract directly confirms DHC is more efficacious than codeine at mu-receptors and does not require O-demethylation for activity.

7,8-saturated codeine congeners (DHC, hydrocodone, oxycodone) are more efficacious than codeine at mu-receptors. DHC does not require O-demethylation for activity, unlike codeine.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPrescrire International argued that so-called weak opioids — including DHC — carry no less risk than low-dose morphine at equivalent analgesic doses^[9]97%

Verified

Abstract directly confirms weak opioids including DHC have same adverse effects as morphine and no evidence they are less addictive.

Review: weak opioids (codeine, DHC, tramadol) have same adverse effects as morphine. No evidence that weak opioids are less addictive than low-dose morphine.

checked by claude-sonnet-4-6 · May 9, 2026

safety23 claims19verified2partial2inconclusive

verifiedRock and colleagues analyzed DHC-related deaths in England from 2001 to 2020 and identified increasing trends in DHC-implicated fatalities over this period^[8]97%

Verified

Paper title confirms 2001–2020 timeframe; abstract confirms trend analysis of DHC-related deaths in England with evidence of increasing misuse in overdose deaths.

DHC considered 'weak' opioid but evidence of increasing misuse in overdose deaths. Analyzes trends in DHC-related deaths in England by source, dose, and demographics.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedKlinder and colleagues reported femoral blood DHM concentrations of 0.16–0.21 mg/L in three fatalities^[28]98%

Verified

Abstract directly confirms femoral blood DHM concentrations of 0.16–0.21 mg/L in three fatal cases.

DHC and metabolites in femoral blood from three fatal cases. DHM concentrations 0.16-0.21 mg/L.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAderjan reported serum DHM concentrations of 0.16–0.22 mg/L in three additional fatal cases^[20]98%

Verified

Abstract directly confirms serum DHM concentrations of 0.16–0.22 mg/L in three patients who died from overdoses.

DHC metabolism studied in three patients who died from overdoses. DHM concentrations 0.16-0.22 mg/L serum.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedBecause DHM has mu-receptor affinity comparable to morphine, DHM accumulation contributes significantly to lethality even when parent DHC concentrations appear relatively low.^[28]95%

Verified

Abstract confirms DHM has similar binding affinity to morphine at mu-receptors and that metabolite determination is important in interpreting cause of death.

DHM has similar binding affinity to morphine at mu-receptors. Metabolite determination important in interpreting cause of death.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedHawton and colleagues studied relative toxicity of analgesics in intentional self-poisoning by comparing case fatality ratios across overdose episodes.^[39]95%

Verified

Abstract confirms the study examines relative toxicity of analgesics using case fatality data from fatal and non-fatal overdoses.

Analgesics used most frequently in fatal and non-fatal medicinal self-poisonings. Knowledge about relative toxicity important for clinicians and regulatory agencies.

checked by claude-sonnet-4-6 · May 9, 2026

partialShimizu and colleagues reported respiratory depression in a 1-month-old neonate receiving prescribed DHC 2 mg/day, with disproportionately high DHC concentrations (400 nmol/L) measured 21 hours post-dose, attributed to developmental immaturity of glucuronidation pathways.^[31]78%

Partial

Abstract confirms neonate case with respiratory depression from prescribed DHC 2mg/d and neonatal clearance impairment from underdeveloped glucuronidation, but the 400 nmol/L concentration and 21-hour timing are not in the abstract.

Neonate case: respiratory depression after prescribed DHC 2mg/d. Neonatal clearance impaired by underdeveloped glucuronidation.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedRenal accumulation of glucuronide metabolites is documented, with potential for prolonged narcosis and respiratory depression in patients with renal insufficiency.^[24]90%

Verified

Abstract confirms case reports of prolonged narcosis with DHC in renal insufficiency.

Case reports of prolonged narcosis with codeine and dihydrocodeine in renal insufficiency. Care needed when prescribing.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedRenal accumulation of glucuronide metabolites is documented, with potential for prolonged narcosis and respiratory depression in patients with renal insufficiency.^[25]88%

Verified

Abstract confirms DHC accumulation in renal failure can explain adverse reactions.

DHC and codeine accumulation may explain adverse reactions in impaired renal function.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedFreye and colleagues demonstrated dose-independent prolongation of oro-cecal transit time at 60 mg and 120 mg controlled-release DHC.^[40]97%

Verified

Abstract directly confirms CR DHC 60 and 120 mg caused prolongation of oro-cecal transit with no significant dose difference between the two doses.

CR DHC 60 and 120 mg caused significant prolongation of oro-cecal transit (constipation). No significant dose difference between 60 and 120 mg for these effects.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPrescrire International argued that so-called weak opioids, including DHC, carry no less risk than low-dose morphine at equivalent analgesic doses — a position supported by comparable rates of respiratory depression, constipation, and dependence.^[9]95%

Verified

Abstract directly confirms weak opioids including DHC have the same adverse effects as morphine and no evidence of less addiction liability.

Review: weak opioids (codeine, DHC, tramadol) have same adverse effects as morphine. No evidence that weak opioids are less addictive than low-dose morphine.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPharmacovigilance data from EudraVigilance and FAERS databases confirm abuse, misuse, and dependence signals for DHC^[12]97%

Verified

Abstract directly confirms pharmacovigilance signals for abuse, misuse, and dependence for DHC in EudraVigilance and FAERS databases.

Pharmacovigilance signals for abuse, misuse, dependence for codeine, DHC, fentanyl, oxycodone, pentazocine, tramadol in EV and FAERS 2003-2018.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedHistorical data from Germany document patterns of compulsive DHC use among polydrug-dependent individuals since the 1960s.^[11]95%

Verified

Abstract directly confirms increasing DHC and codeine abuse in West Germany since the 1960s with case reports on addiction development.

Since 1960s in West Germany, increasing abuse of codeine and dihydrocodeine-containing drugs as substitutes and alternatives. Case reports on addiction development.

checked by claude-sonnet-4-6 · May 9, 2026

partialThe Leeds detoxification study used DHC combined with lofexidine as the standard protocol, implying that DHC itself produces opioid-type physical dependence amenable to structured tapering^[4]75%

Partial

Abstract confirms DHC as the detoxification agent of choice in Leeds, UK, and the RCT context, which supports DHC producing opioid-type dependence amenable to tapering. However, the specific claim of lofexidine combination in the protocol is not mentioned in the abstract.

In Leeds UK, dihydrocodeine is the detoxification agent of choice for heroin users. RCT comparing DHC vs buprenorphine for heroin detoxification in primary care.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMcWhirter and Morris described successful management of kratom withdrawal using DHC, further confirming its capacity to produce and manage opioid-type dependence.^[37]95%

Verified

Abstract directly confirms DHC was effective for kratom withdrawal and demonstrates mu-opioid receptor cross-reactivity.

DHC and lofexidine effective for kratom withdrawal. Demonstrates DHC cross-reactivity with mu-opioid receptor-dependent withdrawal syndromes.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThis combination carries lethal risk.^[9]50%

Inconclusive

The claim is too brief and lacks context for which combination is referred to. While the abstract discusses DHC adverse effects including respiratory depression risks comparable to morphine, it does not specifically address a lethal combination risk.

Review: weak opioids (codeine, DHC, tramadol) have same adverse effects as morphine. DHC respiratory depression in renal failure.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveTramadol: Dual risk mechanism — additive opioid respiratory depression combined with tramadol's SERT inhibition, which introduces theoretical serotonergic risk when other serotonergic agents are co-administered^[17]58%

Inconclusive

Abstract confirms a study of opioid SERT and NET inhibition, but does not specifically confirm tramadol's SERT inhibition magnitude or the dual risk mechanism described.

Opioids may inhibit SERT and NET. Study of different opioids on human SERT, NET and 5-HT receptors.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedSevere hepatic impairment: Reduced first-pass metabolism increases oral bioavailability, and impaired oxidative clearance prolongs drug exposure.^[23]95%

Verified

Abstract directly confirms reduced first-pass metabolism in hepatic cirrhosis increases DHC oral bioavailability.

Hepatic cirrhosis reduces oxidation of opioids; DHC has increased oral bioavailability due to reduced first-pass metabolism in liver disease.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedSevere hepatic impairment: Reduced first-pass metabolism increases oral bioavailability, and impaired oxidative clearance prolongs drug exposure.^[30]95%

Verified

Abstract directly confirms hepatic cirrhosis increases DHC oral bioavailability due to reduced first-pass metabolism and recommends dose reduction.

Hepatic cirrhosis increases oral bioavailability of DHC due to reduced first-pass metabolism. Dose reduction required.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedSevere renal impairment: Glucuronide metabolite accumulation produces prolonged narcosis and respiratory depression.^[24]90%

Verified

Abstract confirms case reports of prolonged narcosis with DHC in renal insufficiency.

Case reports of prolonged narcosis with codeine and dihydrocodeine in renal insufficiency.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedSevere renal impairment: Glucuronide metabolite accumulation produces prolonged narcosis and respiratory depression.^[25]88%

Verified

Abstract confirms DHC accumulation in renal failure may explain adverse reactions.

DHC and codeine accumulation may explain adverse reactions in impaired renal function.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedSevere renal impairment: Glucuronide metabolite accumulation produces prolonged narcosis and respiratory depression.^[26]82%

Verified

Abstract confirms opioid use in renal impairment causes increased adverse effects per systematic review of guidelines.

Opioid use in renal impairment can cause increased adverse effects.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedNeonates and infants: Immature glucuronidation capacity produces disproportionate drug accumulation.^[31]95%

Verified

Abstract directly confirms neonatal clearance is impaired by underdeveloped glucuronidation, causing DHC accumulation.

Neonatal clearance impaired by underdeveloped glucuronidation.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedParalytic ileus or obstructive bowel disease: DHC reduces gastrointestinal motility via peripheral mu-receptor activation.^[40]90%

Verified

Abstract confirms DHC causes significant prolongation of oro-cecal transit time (reduced GI motility), consistent with peripheral mu-receptor activation mechanism.

CR DHC 60 and 120 mg caused significant prolongation of oro-cecal transit (constipation).

checked by claude-sonnet-4-6 · May 9, 2026

Coverage & Gaps

effect links

69 links · 69 approved · 12 audited0/69 with evidence basis

interactions

7 approved pairs0/7 graded

Research Trail

substance-article pipeline-v5 May 9, 2026

Step	Source	Query	Results
1database lookup	PubChem	dihydrocodeine	1 result, 1 selected
selection rationaleselection rationale Primary chemical identity data
2literature search	PubMed	dihydrocodeine pharmacology opioid receptor binding	8 results, 8 selected
selection rationaleselection rationale All highly relevant to DHC pharmacology, binding affinities, and safety
3literature search	PubMed	dihydrocodeine pharmacokinetics bioavailability metabolism	7 results, 5 selected
selection rationaleselection rationale Primary PK data for DHC
4literature search	OpenAlex	dihydrocodeine opioid analgesic	10 results, 3 selected
selection rationaleselection rationale High-quality reviews with direct relevance to DHC pharmacology and clinical use
5literature search	PubMed	dihydrocodeine overdose toxicity death fatality	4 results, 3 selected
selection rationaleselection rationale Critical safety and mortality data
6literature search	PubMed	dihydrocodeine CYP2D6 metabolism dihydromorphine	9 results, 5 selected
selection rationaleselection rationale Core metabolism pathway papers
7clinical trial search	ClinicalTrials.gov	dihydrocodeine	10 results, 1 selected
selection rationaleselection rationale Only specifically DHC-focused trial found
8literature search	PubMed	dihydrocodeine analgesic efficacy clinical trial pain	10 results, 3 selected
selection rationaleselection rationale Clinical efficacy and comparative data for DHC
9literature search	PubMed	dihydrocodeine opioid interaction alcohol respiratory depression	1 result, 1 selected
selection rationaleselection rationale Safety interactions information
10legal status search	WebSearch	dihydrocodeine legal status scheduling DEA UK controlled substance	10 results, 2 selected
selection rationaleselection rationale Authoritative legal status data for major jurisdictions
11document retrieval	WebSearch	dihydrocodeine history synthesis first described 1908	10 results, 2 selected
selection rationaleselection rationale Historical origin data
12legal status search	WebSearch	dihydrocodeine scheduling Australia Canada Germany	10 results, 2 selected
selection rationaleselection rationale Scheduling data for additional jurisdictions
13database lookup	WebSearch/DrugBank	dihydrocodeine SMILES PubChem DrugBank	10 results, 2 selected
selection rationaleselection rationale Chemical identity data
14literature search	PubMed	dihydrocodeine lofexidine opioid detoxification	3 results, 2 selected
selection rationaleselection rationale DHC use in addiction treatment and opioid detoxification
15literature search	PubMed	dihydrocodeine opioid interaction alcohol respiratory depression	3 results, 1 selected
selection rationaleselection rationale Drug interaction mechanism for opioid+alcohol
16cross reference	Crossref/verify_doi	DOI 10.1016/j.pain.2013.12.016	1 result, 1 selected
selection rationaleselection rationale DOI verification for key clinical trial
17literature search	PubMed	dihydrocodeine dyspnea breathlessness palliative care	1 result, 1 selected
selection rationaleselection rationale Evidence for opioid use in palliative dyspnea (DHC application context)
18literature search	PubMed	dihydrocodeine opioid heroin addiction substitution treatment	2 results, 1 selected
selection rationaleselection rationale Historical DHC substitution therapy data in Germany
19web search	WebSearch	dihydrocodeine equianalgesic morphine dose conversion WHO	10 results, 0 selected
selection rationaleselection rationale Gap identified and flagged discarded 10: No specific peer-reviewed confirmation found; flagged as editorial gap
20document retrieval	WebFetch	FPM dose equivalents opioids	0 results, 0 selected
selection rationaleselection rationale Access denied; FPM dose conversion data not retrieved
21data extraction	Research synthesis	Summary of all DHC research findings	42 results, 1 selected
selection rationaleselection rationale Full research synthesis completed

Research document (raw, unedited pipeline output)

# Research Output: Dihydrocodeine

**PSX ID:** PSX-0162  
**Research date:** 2026-05-09  
**Provenance ID:** 81dc0d5f-ba98-4a70-82a9-05ee20693863  
**Total citations registered:** 42

---

## Chemical Identity

**Verified via PubChem CID 5284543** (api_verified):

| Property | Value | Source |
|---|---|---|
| PubChem CID | 5284543 | PubChem API [Ref 36 for web context; PubChem confirmed] |
| Molecular formula | C₁₈H₂₃NO₃ | PubChem CID 5284543 |
| Molecular weight | 301.4 g/mol | PubChem CID 5284543 |
| InChIKey | RBOXVHNMENFORY-DNJOTXNNSA-N | PubChem CID 5284543 |
| CAS number | 125-28-0 | Web-retrieved from Cayman Chemical, ChemSpider [Ref 36] |
| IUPAC name | (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol | PubChem CID 5284543 |
| SMILES | [H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC | DrugBank DB01551 (web-retrieved) |

**Notes on brief seed data:**
- Seed SMILES was blank — filled from DrugBank (web-retrieved, not api_verified via PubChem canonical SMILES endpoint; flag for verification).
- Seed PubChem CID was blank — confirmed as 5284543.
- Seed molecular formula and weight were blank — confirmed C₁₈H₂₃NO₃, 301.4 g/mol.
- Seed IUPAC name matches PubChem exactly. ✓
- Seed systematic name matches the PubChem IUPAC name. ✓

**Chemical class:** Morphinan alkaloid; substituted morphinan. Semi-synthetic opioid derived from codeine by hydrogenation of the 7,8-double bond (converting the double bond between carbons 7 and 8 to a single bond), which increases lipophilicity and modestly increases receptor binding affinity compared to codeine [Ref 13].

---

## History

Dihydrocodeine (DHC) was developed in **Germany in 1908** and **first marketed commercially in 1911** [Ref 36, Ref 25]. It is a semi-synthetic opioid prepared from codeine (a natural opium alkaloid) via catalytic hydrogenation of the C7–C8 double bond. The synthetic route from codeine is well established and produces DHC in high yields. A modern enantioselective total synthesis was reported by Opatz et al. (2014), involving a Grewe cyclization and Noyori asymmetric hydrogenation as key steps (PubMed PMID 25271381, noted but not selected as primary relevance for this article).

DHC entered widespread clinical use as both an analgesic and antitussive agent, primarily in Germany and the United Kingdom. By the early 1960s it was being used in West Germany as a substitute and alternative drug by polydrug users and opioid-dependent individuals [Ref 35], which prompted regulatory attention and eventually prompted its classification under controlled substances legislation across multiple jurisdictions.

In the United Kingdom, DHC has had particular historical significance as an opioid substitution treatment option. In cities such as Leeds, it was the **detoxification agent of choice** for heroin users presenting to community treatment services for much of the late 20th and early 21st centuries [Ref 33].

**FLAG – Brief characterization as "emerging":** The brief characterizes DHC as an "emerging" compound. This is factually incorrect from a historical standpoint — DHC has been in continuous clinical use since 1911, over a century. The "emerging" tag likely reflects a database classification artifact. Flag for editorial correction.

---

## Pharmacology

### Receptor Pharmacology

Dihydrocodeine is a **full agonist at mu (µ)-, delta (δ)-, and kappa (κ)-opioid receptors**, with highest affinity at the mu receptor [Ref 1, Ref 2].

**Receptor binding affinities (Ki values, guinea pig cerebral cortex preparations):**

| Receptor | DHC Ki | Dihydromorphine (DHM) Ki | Relative DHM/DHC affinity |
|---|---|---|---|
| µ (mu) | ~0.3 µmol/L | ~0.004 µmol/L (inferred: ≥70× greater) | ~70× greater [Ref 1] |
| δ (delta) | ~5.9 µmol/L (DHC-6-O-glucuronide had 2× affinity) | — | — [Ref 1] |
| κ (kappa) | Lower than µ; DHC-6-O-glucuronide and DHM-6-O-glucuronide had lower κ affinity | — | — [Ref 1] |

Schmidt et al. (2002 [Ref 1]) demonstrated that **dihydromorphine (DHM)** — the primary active metabolite produced via CYP2D6 O-demethylation — has **at least 70× greater mu-receptor affinity** than the parent compound dihydrocodeine. DHM-6-O-glucuronide showed similarly high mu affinity, comparable to morphine-6-glucuronide [Ref 8]. NorDHC had almost identical affinity to DHC at the mu receptor (Ki ~14 µmol/L) [Ref 1].

Mignat et al. (1995 [Ref 2]) established in guinea pig brain homogenates that substitution of the free phenolic hydroxyl group (as occurs in DHC relative to morphine: C-3 methoxy instead of hydroxyl) **substantially decreases receptor binding** without altering the mu/delta selectivity ratio. Glucuronidation at the 6-hydroxy position does not affect mu affinity but alters selectivity toward delta and kappa receptors.

### G-Protein Activation

Thompson et al. (2004 [Ref 4]) measured agonist-stimulated [³⁵S]GTPγS binding and found that 7,8-saturated codeine congeners — including DHC — were **more efficacious than codeine** at stimulating mu-receptor-mediated G-protein activation. DHC was the only compound in this class also more efficacious than codeine at delta receptors. Importantly, this study provides a mechanistic explanation for why DHC analgesia does not strictly require O-demethylation to DHM: DHC itself is a more efficacious mu-receptor G-protein activator than its parent compound codeine [Ref 4].

### Serotonin and Noradrenaline Transporters

Rickli et al. (2018 [Ref 5]) examined opioid-induced inhibition of human SERT and NET in vitro. The study found that several opioids (notably tramadol, tapentadol, methadone, dextromethorphan, and pethidine) inhibit SERT, which may contribute to serotonin syndrome risk. The abstract does not name DHC as a primary SERT inhibitor. **DHC does not appear to be a clinically significant SERT or NET inhibitor based on available evidence.** The serotonin syndrome risk in combination with tramadol (which is a potent SERT inhibitor) likely derives primarily from tramadol's pharmacology rather than DHC's. This flag should be communicated to the generation agent: do NOT describe DHC as a serotonin syndrome-causing agent independently.

### Pharmacological Class Note

The brief lists DHC's pharmacological class as including "Kappa-opioid receptor agonist." This is technically supported (DHC does bind kappa receptors), but this framing overstates the importance of kappa activity. Published binding data consistently shows DHC's primary mechanism is **mu-opioid receptor agonism**, with significantly lower affinity at delta and kappa sites [Ref 1, Ref 2]. The generation agent should present DHC primarily as a mu-opioid agonist.

---

## Pharmacokinetics

### Absorption and Bioavailability

Rowell et al. (1983 [Ref 9]) conducted the foundational human PK study with oral (30mg, 60mg) and IV (30mg, 50mg) dosing in healthy volunteers and clinical patients. Key findings:
- **Oral bioavailability: ~21%** (range 12–34%) after oral administration [Ref 9]
- This low bioavailability is attributable to **substantial first-pass hepatic metabolism** [Ref 9]
- **Tmax: 1.6–1.8 hours** after oral dosing [Ref 9]
- Mean peak concentrations at 1.6–1.8h [Ref 9]

Cowan et al. (1988 [Ref 41]) confirmed that a controlled-release formulation (DHC-bitartrate 90mg) and immediate-release solution (3 × 30mg) achieved **comparable total bioavailability** (AUC), with mean urinary recovery of ~30mg in each arm [Ref 41]. The sustained-release formulation produced effective steady-state plasma concentrations regardless of food timing, with no accumulation over 4-day dosing [Ref 41].

### Distribution and Half-Life

- **Intravenous kinetics:** Two-compartment distribution model [Ref 9]
- **Elimination half-life: 3.3–4.5 hours** (parent compound, from Rowell 1983 [Ref 9])
- In pediatric patients: apparent half-life ~3 hours in a 14-year-old (CYP2D6 EMs), with clearance primarily through DHC glucuronidation and partial O-demethylation [Ref 16]
- In neonates: markedly prolonged due to underdeveloped glucuronidation capacity, leading to accumulation [Ref 16]

### Metabolism

DHC undergoes several parallel metabolic pathways:

1. **O-demethylation → Dihydromorphine (DHM):** Catalyzed by **CYP2D6** [Ref 11, Ref 12]. DHM has ~70× greater mu-receptor affinity than DHC [Ref 1] and similar pharmacological properties to morphine. Fromm et al. (1995 [Ref 11]) were the first to characterize DHC as a CYP2D6 substrate. Kirkwood et al. (1997 [Ref 12]) subsequently characterized the full suite of CYP enzymes using human liver microsomes.

2. **N-demethylation → Nordihydrocodeine (norDHC):** Catalyzed by **CYP3A4** [Ref 12]. NorDHC has similar, low mu-receptor affinity to DHC [Ref 1].

3. **Glucuronidation:** DHC-6-O-glucuronide, DHM-3-O-glucuronide, and DHM-6-O-glucuronide are formed. DHM-6-O-glucuronide has high mu affinity comparable to morphine-6-glucuronide [Ref 8].

**Steady-state pharmacokinetics** (Ammon et al. 1999 [Ref 10]):  
In 12 healthy CYP2D6 extensive metabolizers (EMs), single oral dose (60mg) and multiple oral doses (60→90→120mg BID) were studied. AUC, Cmax, and Cssmin showed **dose-linear** behavior across all doses for both DHC and DHM. O-demethylation to DHM remained constant across increasing steady-state doses, confirming no saturation of CYP2D6 at clinically relevant doses [Ref 10].

### CYP2D6 Pharmacogenomics

Approximately **7% of Caucasians are CYP2D6 poor metabolizers (PMs)**, leading to reduced or absent DHM formation [Ref 1]. In CYP2D6 PMs, DHC analgesia may be somewhat reduced, but — in contrast to codeine — DHC retains meaningful mu-receptor activity as a parent compound [Ref 4, Ref 13]. This means **therapeutic failure is less complete in DHC PMs than in codeine PMs** [Ref 13]. Conversely, CYP2D6 ultrarapid metabolizers (UMs) may produce excessive DHM, increasing overdose risk. Case reports of respiratory depression in neonates (Shimizu 2018 [Ref 16]) illustrate the PK complexity, though the neonatal cases were primarily explained by developmental immaturity of glucuronidation rather than CYP2D6 genotype.

Crews et al. (2021 [Ref 21], CPIC guideline) covers CYP2D6 genotype-based prescribing for opioids including codeine and tramadol; DHC is not separately addressed in CPIC guidelines, further distinguishing it from codeine in terms of CYP2D6 dependence.

### Hepatic and Renal Disease

- **Liver disease:** Hepatic cirrhosis reduces oxidative metabolism, resulting in **increased oral bioavailability** of DHC due to reduced first-pass extraction, and decreased overall clearance [Ref 22, Ref 40]. Dose reduction is required in significant hepatic impairment.
- **Renal disease:** Metabolites (particularly glucuronides) are renally excreted. Case reports document **prolonged narcosis and respiratory depression** in patients with renal insufficiency receiving DHC [Ref 30, Ref 31]. Particular caution and dose reduction are required in renal failure [Ref 29].

---

## Discovery and Synthesis History

- **Year developed:** 1908 (Germany) [Ref 36, Ref 25]
- **Year first marketed:** 1911 [Ref 36]
- **Method:** Hydrogenation of the C7–C8 double bond of codeine; the resulting 7,8-dihydro derivative is dihydrocodeine
- **Alternative total synthesis:** Enantioselective synthesis reported in 2014 (Opatz), via Grewe cyclization and Noyori asymmetric hydrogenation (PMID 25271381, noted but not primary-relevance selected)
- **Patent route:** Preparation from codeine (US patent US6887999B1) [web-retrieved]
- **First clinical applications:** Analgesic and antitussive in Germany, early 20th century

---

## Subjective Effects

Published controlled studies in humans document the following subjective and objective effects:

**Central opioid effects documented in controlled studies:**

- **Sedation / fatigue / tiredness:** Reported in 80% of volunteers receiving CR-DHC 60mg or 120mg orally (Freye et al. 2001 [Ref 6])
- **Dry mouth:** Reported in 80% of volunteers in same study [Ref 6]
- **Miosis (pupil constriction):** Significant depression of pupillary light reflex from 53.9mm (control) to 8.3–7.4mm in controlled dose study; dose-independent between 60 and 120mg [Ref 6]
- **Constipation / delayed oro-cecal transit:** DHC significantly prolonged oro-cecal transit time (H₂-exhalation test) compared to placebo; effect not significantly dose-dependent between 60 and 120mg CR-DHC [Ref 6]
- **Nausea, vomiting, drowsiness:** Reported as principal adverse effects in RCT following third molar surgery (McQuay et al. 1993 [Ref 26]); DHC 60mg produced 4× higher adverse event rates than ibuprofen [Ref 26]
- **Vertigo:** Reported in 5% of volunteers in controlled study [Ref 6]
- **Headache:** Reported in 1% of volunteers [Ref 6]
- **Euphoria:** Expected from mu-opioid mechanism; no controlled study directly measures subjective euphoria for DHC in recreational context; class effect assumed
- **Respiratory depression:** Documented in overdose cases and case reports; principal cause of fatal outcomes [Ref 7, Ref 8]
- **Pain relief (analgesia):** Single-dose Cochrane review (Edwards 2000 [Ref 25]) confirms analgesic efficacy for postoperative pain. DHC demonstrated meaningful analgesia in chronic non-malignant pain RCT (Pedersen 2014 [Ref 17]) and neuropathic pain comparison (Frank 2008 [Ref 18]).
- **Antitussive:** Established therapeutic use; no placebo-controlled DHC-specific trial abstract retrieved; class-level evidence is robust.
- **Dyspnea relief:** Opioids (including DHC class) are established for dyspnea management in palliative care (Jennings 2002 [Ref 32]; Viola 2008 [Ref 37, not in registry yet — see note]).

**Duration:** Immediate-release DHC onset within ~1–2h (Tmax 1.6–1.8h) [Ref 9]; duration of analgesia approximately 4–6 hours for immediate-release formulations based on half-life and clinical practice; controlled-release formulations (DHC Continus 60mg or 120mg) provide prolonged effect. The brief states 3–4 hours total duration for oral route — this likely refers to immediate-release and is plausible but specific duration data from controlled human studies is limited.

**Potency comparison:**
- Leppert & Woron (2016 [Ref 13]) state DHC analgesic effect is **similar to codeine** and **approximately twice as potent as tramadol** orally.
- A commonly cited equianalgesic conversion in clinical practice is 100mg oral DHC ≈ 10mg oral morphine (1/10 potency ratio), but **no specific published pharmacodynamic study directly confirms this ratio with DHC-specific data** — see Gaps & Flags.

---

## Safety & Toxicity

### Fatal Overdose

**Rock et al. (2022 [Ref 14])** analyzed DHC-related deaths in England from 2001–2020, finding increasing trends in DHC-implicated overdose fatalities. This study raises safety concerns about DHC being underclassified as a "weak" opioid, while its misuse and mortality patterns mirror those of stronger opioids.

**Klinder et al. (1999 [Ref 7])** and **Aderjan & Skopp (1998 [Ref 8])** reported post-mortem data from three DHC fatalities each. DHM concentrations in femoral blood ranged **0.16–0.21 mg/L** [Ref 7] and **0.16–0.22 mg/L serum** [Ref 8]. Because DHM has binding affinity similar to morphine at mu-receptors, DHM accumulation may contribute significantly to lethality even when parent DHC concentrations appear relatively low [Ref 7].

**Hawton et al. (2019 [Ref 15])** studied relative toxicity of analgesics in intentional self-poisoning, comparing case fatality ratios across overdose episodes.

**Shimizu et al. (2018 [Ref 16])** reported overdose cases in two pediatric patients genotyped as CYP2D6\*1/\*10-\*36:
- **1-month-old neonate:** Respiratory depression after prescribed DHC 2mg/day (divided twice daily). High DHC (400 nmol/L) and DHM (1.9 nmol/L) concentrations 21h after last dose. Attributed to impaired neonatal glucuronidation [Ref 16].
- **14-year-old girl:** Overdose on 37mg DHC. Apparent half-life ~3h; rapid clearance via glucuronidation and O-demethylation [Ref 16].

### Respiratory Depression

Respiratory depression is the primary mechanism of DHC-related death. It occurs via mu-opioid receptor-mediated inhibition of brainstem respiratory centers. Risk is amplified by:
- Concurrent CNS depressants (alcohol, benzodiazepines, GHB/GBL, ketamine)
- Renal or hepatic impairment [Ref 30, Ref 31, Ref 40]
- CYP2D6 ultrarapid metabolism (excessive DHM formation)
- Neonatal/pediatric age (immature glucuronidation) [Ref 16]
- Fixed-dose extended-release formulations used outside prescribed intent

### Organ Toxicity

- **No specific hepatotoxicity** from DHC described in reviewed literature.
- **Renal accumulation** of glucuronide metabolites is documented [Ref 30, Ref 31].
- **GI effects:** Constipation via peripheral mu-opioid receptor activation in the myenteric plexus (Freye 2001 [Ref 6]).
- **Endocrine effects:** Class-level opioid-induced endocrinopathy (hypogonadism, hypocortisolism) applies at chronic exposure; no DHC-specific data retrieved.

### Toxicity in the "Weak Opioid" Context

Prescrire International (2016 [Ref 19]) argues that so-called weak opioids — including DHC — carry no less risk than low-dose morphine. Respiratory depression cases with DHC in renal failure are documented [Ref 19]. There is no evidence that DHC is less addictive than low-dose morphine at equivalent analgesic efficacy [Ref 19].

### LD50

No published LD50 data for DHC in humans or animals was retrieved in this research. **Flag for generation agent: do not include an LD50 value for DHC; state that animal and human LD50 data were not identified in published literature.**

---

## Harm Reduction

Based on published literature:

1. **Avoid combining with CNS depressants:** Alcohol, benzodiazepines, GHB/GBL, ketamine, and other opioids all produce additive or synergistic respiratory depression. Lethal interactions documented for alcohol, GHB, GBL, and ketamine (from brief interactions data; consistent with general opioid pharmacology).

2. **Do not use in renal or hepatic impairment without medical supervision:** Metabolite accumulation documented; narcosis and respiratory depression reported [Ref 30, Ref 31, Ref 40].

3. **Avoid use in infants and neonates:** Immature glucuronidation leads to disproportionate accumulation [Ref 16].

4. **Extended-release formulations carry elevated overdose risk if chewed or crushed:** Normal-release kinetics are disrupted, leading to rapid dose dumping.

5. **Controlled-release doses should not be escalated without titration:** While linear PK was shown in EMs up to 120mg BID [Ref 10], individual variation is substantial.

6. **Tramadol combination:** The brief lists this as "lethal." Published evidence suggests the primary mechanism is additive opioid CNS/respiratory depression. Tramadol is also a SERT inhibitor [Ref 5], which may theoretically add serotonergic risk; however, DHC is not a known SERT inhibitor. This combination should be flagged as high-risk due to combined CNS depression.

7. **Naloxone reversal:** As a mu-opioid agonist, DHC overdose is reversible with naloxone. Adequate dosing may be required given DHM's high potency.

8. **Testing:** DHC can be detected via HPLC, GC-MS, or immunoassay. Commercially available opioid immunoassays may cross-react with DHC.

---

## Tolerance & Dependence

### Tolerance

Tolerance to DHC's opioid effects (analgesia, respiratory depression, euphoria) develops with **prolonged and repeated use** via standard mu-opioid receptor mechanisms (receptor desensitization, downregulation of signaling). The brief states:
- **Buildup:** Develops with prolonged and repeated use ✓ (consistent with pharmacological class; no DHC-specific published rate data found)
- **Half-life for tolerance:** 5 days [from brief — **FLAG: no published source confirming this specific value for DHC found; may be editorial estimate**)
- **Full reset:** 1.5 weeks [from brief — **FLAG: same; no published primary source confirming DHC-specific tolerance reset timeline found**)
- **Cross-tolerance:** All opioids (via shared mu receptor mechanism) ✓

### Dependence

DHC produces **physical and psychological dependence** with repeated use, consistent with its status as a mu-opioid agonist. Published data:

- **Physical dependence:** Documented through use of DHC in opioid substitution treatment; withdrawal is managed similarly to short-acting opioid withdrawal [Ref 33, Ref 34]
- **Psychological dependence:** Documented; compulsive use and misuse patterns reported in Germany since the 1960s [Ref 35]
- **Abuse potential:** Pharmacovigilance data (Chiappini et al. 2022 [Ref 38]) confirm abuse, misuse, and dependence signals for DHC in EudraVigilance and FAERS databases [Ref 38]
- **Detoxification:** DHC+lofexidine is an established approach for managing opioid withdrawal, suggesting DHC itself produces opioid-type physical dependence that can be clinically managed [Ref 33, Ref 34]
- **Formation:** The brief states "moderately addictive with a high potential for abuse" — consistent with published evidence and class characteristics. However, no DHC-specific controlled study of dependence formation rate was retrieved.

### Withdrawal Symptoms

By class analogy (no DHC-specific published characterization retrieved), opioid withdrawal from DHC would follow the standard short-acting opioid withdrawal pattern: anxiety, restlessness, irritability, dysphoria, myalgia, lacrimation, rhinorrhea, yawning, insomnia, diarrhea, nausea, vomiting, and cravings. McWhirter & Morris (2010 [Ref 34]) describe kratom withdrawal (which shares opioid character) being successfully managed with DHC, implying DHC itself produces opioid-type dependence amenable to structured tapering.

---

## Interactions

| Combination | Severity (Brief) | Evidence Type | Mechanism |
|---|---|---|---|
| Alcohol (ethanol) | **Lethal** | Class-level pharmacodynamic | Additive CNS and respiratory depression via mu-opioid + ethanol GABA/NMDA effects [Ref 19] |
| GHB/GBL | **Lethal** | Class-level pharmacodynamic | Additive CNS depression; GHB acts via GABA-B receptors and GHB-specific receptors |
| Ketamine | **Lethal** | Class-level pharmacodynamic | Additive respiratory/CNS depression; ketamine NMDA antagonism may synergize with opioid-induced apnea |
| Tramadol | **Lethal** | Class-level; partially published | (1) Additive opioid respiratory depression; (2) tramadol's SERT inhibition [Ref 5] adds theoretical serotonergic risk, though DHC is not a SERT inhibitor |
| Nitrous oxide | Unknown | No published data found | Opioid + N₂O may cause enhanced sedation; nitrous is weak mu agonist |
| PCP | Unknown | No published data found | — |

**CYP2D6 inhibitors** (e.g., fluoxetine, paroxetine, bupropion): Would reduce DHC's conversion to DHM, potentially reducing analgesic effect and attenuating opioid toxicity — a pharmacokinetic interaction relevant to prescribing context.

**CYP3A4 inducers/inhibitors:** Would alter norDHC formation. Clinical significance is secondary to CYP2D6 effects.

**MAO inhibitors:** As a general opioid class caution, DHC should not be combined with MAOIs due to risk of unpredictable serotonergic and opioidergic reactions. No DHC-specific case reports were retrieved.

**Serotonin syndrome risk with tramadol:** Tramadol is a known SERT inhibitor [Ref 5]. Combined with other serotonergic agents, it poses serotonin syndrome risk independent of DHC. The interaction severity as "lethal" is primarily explained by additive respiratory depression, not serotonin syndrome from DHC specifically.

---

## Legal Status

| Jurisdiction | Status | Details |
|---|---|---|
| **United States** | Schedule II (CSA) | Pure dihydrocodeine. Some combination products carry lower scheduling [Ref 36 web]. DEA orangebook lists DHC as NARC, CSA Schedule II. |
| **United Kingdom** | Class B; Schedule 5 (Misuse of Drugs Regulations 2001) | Available OTC as <8mg combined with paracetamol. Schedule 5 exempts possession if ≤100mg per preparation (≤2.5%) and not designed for injection [Ref 36]. Possession otherwise: up to 5 years imprisonment or unlimited fine. |
| **Australia** | Schedule 8 (pure); Schedule 4 (combination, ≤100mg/dose); Schedule 3 (cough, ≤15mg/dose with other agents) | Tiered scheduling based on preparation and dose [Ref 36] |
| **Germany** | Betäubungsmittelgesetz (BtMG) | Controlled at similar level to codeine under narcotic law [Ref 36]. Historically used as a registered substitution agent for opioid dependence. |
| **Canada** | Controlled; prescription required | Appears in Schedule I (Controlled Drugs and Substances Act) at Schedule I as a controlled narcotic. Specific scheduling details not fully confirmed in retrieved sources — **FLAG for editorial verification.** |
| **International** | UN 1961 Single Convention on Narcotic Drugs | Listed as a Schedule II substance internationally [Ref 36] |

---

## Clinical Trials

**NCT00547885 — "Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-malignant Pain"**
- **Status:** COMPLETED
- **Phase:** 4
- **Condition:** Chronic non-malignant pain
- **Sponsor:** Norwegian University of Science and Technology
- **Published results:** Pedersen et al. (2014) in *Pain* [Ref 17, DOI: 10.1016/j.pain.2013.12.016 — verified via Crossref]
- **Key finding:** 8-week RCT (n=60) comparing DHC-Continus (long-acting) vs short-acting DHC tablets. **No significant difference** in pain stability, sleep quality, depression, QoL, or adverse events between arms. Long-acting DHC not superior [Ref 17].

**NCT00576017** — Fentanyl-TTS vs weak opioids (including DHC) in cancer pain (COMPLETED, Phase 4, Janssen): Broader trial comparing fentanyl patch to step-2 opioids; DHC used as one of the weak opioid comparators.

**Leeds LEEDS Study (ISRCTN07752728)** — RCT of DHC vs buprenorphine for heroin/methadone detoxification in primary care (UK) [Ref 33]. Published 2004 as protocol paper; see Oldham et al. 2004.

No active recruiting trials specifically for DHC were identified.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No feedback items to investigate or report.

---

## Gaps & Flags

### Chemical Data Gaps
1. **SMILES not api_verified:** The SMILES string was retrieved from DrugBank (web-retrieved), not confirmed via PubChem canonical SMILES API. Generation agent should note this and flag for chemical verification. Seed SMILES was blank — the retrieved value fills the gap but with moderate confidence only.
2. **PubChem CID not in brief:** Brief had blank PubChem CID field. Confirmed as 5284543 via PubChem API lookup.

### Pharmacology Gaps
3. **Kappa agonist classification in brief:** The brief includes "Kappa-opioid receptor agonist" as a pharmacological class. Published data shows kappa affinity is significantly lower than mu affinity and is not a primary mechanism. Recommend revising pharmacological class to focus on mu-opioid agonism, with delta activity noted as secondary and kappa as incidental.
4. **Equianalgesic ratio:** A commonly cited clinical conversion of 100mg oral DHC ≈ 10mg oral morphine (i.e., DHC is ~1/10 the potency of oral morphine) appears in clinical practice guides but no peer-reviewed pharmacodynamic study specifically confirming this ratio for DHC was retrieved. Leppert (2016 [Ref 13]) states DHC is approximately 2× more potent than tramadol orally (and roughly equivalent to codeine). **Safety-critical flag: do not publish a specific equianalgesic dose without editorial verification against primary sources.**
5. **No LD50 data:** No animal or human LD50 values for DHC were identified in published literature. Generation agent should state this absence.
6. **DHC-specific serotonin syndrome reports:** No DHC-specific case reports of serotonin syndrome were retrieved. The Rickli 2018 [Ref 5] paper studied multiple opioids and DHC was not specifically named as a significant SERT inhibitor. Tramadol's SERT inhibition is the primary concern in the DHC+tramadol combination — not a DHC-intrinsic effect.
7. **Antitussive evidence:** No DHC-specific placebo-controlled RCT of antitussive efficacy was retrieved. This is an established clinical use backed by long clinical tradition and pharmacological mechanism but lacks modern evidence base.

### Duration Gap
8. **Duration data (3–4h oral):** Consistent with the elimination half-life of 3.3–4.5h from Rowell 1983 [Ref 9]. However, this applies only to immediate-release formulations. Controlled-release formulations (DHC-Continus) extend duration significantly (12-hour dosing intervals are used clinically). Generation agent should specify duration by formulation type.

### Tolerance/Dependence Gaps
9. **Tolerance half-life and reset values:** The brief states half-life of tolerance 5 days and full reset 1.5 weeks. **No published DHC-specific study confirming these values was found.** These may be editorial estimates based on opioid class analogy. Flag for human editorial review — mark as inferred from class rather than DHC-specific data.

### Legal Status Gap
10. **Canada scheduling:** Specific schedule under Canada's Controlled Drugs and Substances Act not confirmed from retrieved sources. **Safety-critical flag for editorial verification.**

### Characterization Gap
11. **"Emerging" characterization in brief:** DHC has been in clinical use since 1911. The "emerging" classification appears to be a database artifact. Recommend correcting to reflect established clinical history.

### Safety-Critical Value Flags
- **Dose ranges in brief:** Brief dose ranges (threshold 20mg, light 50–100mg, common 100–150mg, strong 150–200mg, heavy 200mg+) are **plausible** for oral immediate-release DHC, and roughly consistent with clinical therapeutic doses (30–120mg BID in published studies [Refs 6, 10, 17]), but no published controlled study specifically delineates recreational dose ranges for non-clinical use. **Flag: dose ranges should be noted as based on clinical data and community consensus rather than controlled recreational-use study data.**
- **Interaction severity "lethal" for tramadol:** Plausible via additive respiratory depression, but the "lethal" classification is stronger than what appears in published drug interaction databases. Tramadol's SERT inhibition does not appear to be the primary DHC-tramadol risk. **Flag for harm reduction accuracy review.**

Dihydrocodeine

Value Provenance

Dosing

oraltrace →

Duration

oral

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

oral

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

Research Trail

oraltrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace